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There is a growing demand for non-surgical means of cataract treatment. This 
dissertation presents three bodies of work that reflect the early-stage development of eye 
drop formulations aimed at delaying cataract progression. These formulations consist of 
the antioxidant 2-mercaptopropionylglycine (MPG) loaded onto nanodiamond particles.
Cataractogenesis is linked to oxidative damage to lens proteins. To investigate the 
potential of MPG for protection against oxidative damage, A549 cells were incubated in
0.6 mM tert-butylhydroperoxide (tBHP). Cells exposed to tBHP without MPG exhibited 
elevated levels of reactive oxygen species, which led to the depletion of the vital 
antioxidant glutathione and, ultimately, apoptosis. Co-administration of 5 mM MPG 
protected cells from tBHP-induced damage, resulting in maintenance of cell viability.
To monitor the uptake and fate of MPG in the eye, a rapid, high sensitivity HPLC 
method was developed for the analysis of MPG and its metabolite, 2-mercaptopropionic 
acid, in ocular tissues. Method validation experiments demonstrated the reliability of this 
method for quantifying MPG uptake and evaluating drug delivery strategies.
Achieving effective drug concentrations in the lens poses a major challenge. 
Nanodiamond is biocompatible, and its surface chemistry can be tailored to specific 
applications. Thus, it is emerging as a candidate of interest for drug delivery. 
Nanodiamond surfaces were functionalized with carboxyl (ND-COOH), hydroxyl (ND- 
OH), and amino (ND-NH2) groups to investigate the effect of ND surface chemistry on 
adsorption and release of MPG. The ND-NH2 exhibited the highest adsorption capacity, 
but the ND-OH was the most effective for sustained release.
v
ACKNOWLEDGMENTS
Firstly, I would like to thank my advisor, Dr. Nuran Ercal, for her continued 
support and guidance throughout my residence at Missouri S&T. She has provided me 
with countless opportunities for growth and development as a scientist.
I would also like to thank Dr. Vadym Mochalin and the members of my 
committee, Drs. Klaus Woelk, Lia Leventis, Honglan Shi, and Yue-Wern Huang.
I am thankful for the mentorship and camaraderie provided by my former and 
current research group members, especially Annalise Pfaff, Hsiu-Jen Wang, Yasaswi 
Maddirala, Anna Chernatynskaya, and Ibrahim Abdullahi.
I must also acknowledge the late Richard K. Vitek, whose financial contributions 
supported the research activities and scientific development of myself as well as 
countless other students.
Finally, I would like to thank my friends and family for encouraging me through 





PUBLICATION DISSERTATION OPTION................................................................... iii
ABSTRACT....................................................................................................................... iv
ACKNOWLEDGMENTS.................................................................................................. v





1.1. GLOBAL HEALTH IMPACT OF CATARACTS............................................ 1
1.2. CATARACTOGENESIS AND AVENUES FOR TREATMENT.................... 1
1.2.1. Tiopronin...................................................................................................3
1.2.2. Eye Drops Are the Preferred Route of Administration.............................4
1.2.3. Drug Delivery Vehicles Can Promote MPG Uptake and Efficacy...........4
1.2.4. Nanodiamond Drug Delivery....................................................................4
1.3. DEVELOPMENT AND EVALUATION OF ND:MPG FORMULATIONS ... 6 
PAPER
I. PROTECTIVE EFFECTS OF TIOPRONIN ON OXIDATIVELY 
CHALLENGED HUMAN LUNG CARCINOMA EPITHELIAL CELLS (A549) .. 7
ABSTRACT................................................................................................................... 7
1. INTRODUCTION.................................................................................................... 8
2. MATERIALS AND METHODS 10
2.1. CHEMICALS AND REAGENTS.................................................................... 10
2.2. CELL CULTURE AND PRELIMINARY EXPERIMENTS.......................... 11
2.3. EXPERIMENTAL DESIGN............................................................................ 12
2.4. CELL VIABILITY............................................................................................13
2.5. QUANTIFICATION OF INTRACELLULAR GSH LEVEL.......................... 13
2.6. FLOW CYTOMETRY ANALYSIS OF APOPTOTIC CELLS AND
INTRACELLULAR ROS MEASUREMENT..................................................15
2.7. FLOW CYTOMETRY DETERMINATION OF MITOCHONDRIAL
SUPEROXIDE..................................................................................................16
2.8. STATISTICAL ANALYSIS............................................................................ 17
3. RESULTS AND DISCUSSION.............................................................................. 17
3.1. SELECTION OF DOSING CONCENTRATIONS..........................................17
3.2. EFFECT OF MPG ON INTRACELLULAR GSH IN OXIDATIVELY
CHALLENGED A549 CELLS........................................................................ 20
3.3. EFFECT OF MPG ON VIABILITY OF OXIDATIVELYCHALLENGED
A549 CELLS.................................................................................................... 20
3.4. EFFECT OF TREATMENT ON APOPTOTIC AND NECROTIC CELL
POPULATIONS..............................................................................................  22
3.5. DISTRIBUTION OF CELLS WITH ROS PRESENT IN APOPTOTIC
AND NON-APTOPTOTIC SUBPOPULATIONS.......................................... 24
3.6. DISTRIBUTION OF SUPEROXIDE PRESENT IN MITOCHONDRIA






DATA AVAILABILITY STATEMENT AND DATA DEPOSITION...................... 30
REFERENCES............................................................................................................. 30
II. SIMULTANEOUS DETERMINATION OF TIOPRONIN AND ITS PRIMARY 
METABOLITE IN PLASMA AND OCULAR TISSUES BY HPLC.................... 35
ABSTRACT................................................................................................................. 35
1. INTRODUCTION.................................................................................................... 36
2. EXPERIMENTAL METHODS............................................................................... 40
2.1. CHEMICALS AND REAGENTS.................................................................... 40
2.2. ANIMALS........................................................................................................ 41
2.3. SAMPLE PREPARATION.............................................................................. 41
2.4. PREPARATION OF CALIBRATION STANDARDS.................................... 42
2.5. HPLC PARAMETERS..................................................................................... 43
2.6. METHOD VALIDATION............................................................................... 44
2.6.1. Selectivity............................................................................................... 44
2.6.2. Linearity and LLOQ............................................................................... 44
2.6.3. Sample Stability...................................................................................... 44
2.6.4. Precision, Accuracy, and Recovery........................................................ 45
3. RESULTS AND DISCUSSION.............................................................................. 45
3.1. CHROMATOGRAPHY................................................................................... 46
3.2. SELECTIVITY................................................................................................. 49
3.3. LINEARITY AND LLOQ................................................................................ 49
3.4. SAMPLE STABILITY..................................................................................... 51
viii
3.5. PRECISION, ACCURACY, AND RECOVERY 53
ix
3.6. DETERMINATION OF MPG AND MPA IN PLASMA AND OCULAR
TISSUES.......................................................................................................... 53
4. CONCLUSION...................................................................................................... 55
ACKNOWLEDGMENTS ...........................................................................................  56
REFERENCES ............................................................................................................  56
III. EFFECT OF NANODIAMOND SURFACE CHEMISTRY ON
ADSORPTION AND RELEASE OF TIOPRONIN.............................................. 59
ABSTRACT................................................................................................................. 59
1. INTRODUCTION.................................................................................................... 60
2. EXPERIMENTAL METHODS............................................................................... 63
2.1. MATERIALS AND REAGENTS.................................................................... 63
2.2. PURIFICATION AND SURFACE MODIFICATION OF ND....................... 63
2.3. CHARACTERIZATION OF FUNCTIONALIZED N D ................................. 65
2.4. ADSORPTION STUDY................................................................................... 66
2.5. RELEASE STUDY........................................................................................... 68
3. RESULTS AND DISCUSSION.............................................................................. 69
3.1. CHARACTERIZATION OF FUNCTIONALIZED N D ................................. 69
3.2. ADSORPTION OF TIOPRONIN.................................................................... 73
3.3. RELEASE STUDY........................................................................................... 77
4. CONCLUSION .......................................................................................................  81
FUNDING ...................................................................................................................  82
AUTHOR CONTRIBUTIONS.................................................................................... 82






2.1. TO WHAT EXTENT DOES MPG PROTECT CELLS AGAINST ACUTE
OXIDATIVE INSULT?................................................................................... 89
2.2. HOW WILL MPG BE MEASURED IN CELL AND ANIMAL
MODELS?........................................................................................................ 90
2.3. WHAT IS THE OPTIMAL ND SURFACE CHEMISTRY FOR
ADSORPTION AND RELEASE OF MPG?................................................... 91






Figure 1. A. Plot of cell viability vs. tBHP concentration. B. Plot of intracellular
GSH concentration vs. tBHP concentration........................................................18
Figure 2. Plot of intracellular GSH concentration vs. dosing concentration of MPG.........19
Figure 3. A. Plot of treatment vs. intracellular GSH concentration. B. Plot of
treatment vs. cell viability.................................................................................. 21
Figure 4. Representative dot-plots from flow cytometry analysis of apoptotic cells........23
Figure 5. Representative dot-plots from flow cytometry analysis of ROS in apoptotic
and live subpopulations...................................................................................... 25
Figure 6. Representative dot-plots of from flow cytometry analysis of superoxide in
mitochondria..................................................................................................... 27
PAPER II
Figure 1. Hydrolysis of MPG to MPA.............................................................................. 37
Figure 2. Derivatization of thiols with ThioGlo-3.............................................................40
Figure 3. Overlay of representative chromatograms from samples containing 
A, ThioGlo-3 in sample diluent; B, ThioGlo-3 + TCEP;
C, ThioGlo-3 + TCEP + NAC; D, ThioGlo-3 + TCEP + NAC + MPA;
E, ThioGlo-3 + TCEP + NAC + MPG + MPA.................................................47
Figure 4. Derivatization of thiols containing a stereocenter gives rise to products
with two stereocenters........................................................................................ 48
Figure 5. Representative chromatograms from processed tissue samples..........................50
Figure 6. Calibration curves for MPG (left) and MPA (right) diluted in SBB.................... 51
PAPER III
Figure 1. Tiopronin microspecies in equilibrium............................................................. 61
Figure 2. A. Low resolution and B. High resolution TEM micrographs of
ND-COOH showing 0.206 nm d-spacing. C. Selected area electron 
diffraction pattern of ND-COOH sample consistent with small ND primary 
particle size and diffraction rings corresponding to the (111), (220), and 
(311) planes of diamond....................................................................................70
Figure 3. A. XRD pattern of as-received ND. B. FTIR spectra of as-received ND, 
ND-COOH, ND-OH, and ND-NH2. C. FTIR spectra of ND-COOH and 
ND-NH2 in the range of wavelength corresponding to Amide bands.
D. Z -potential vs. pH and E. Mean diameter of ND agglomerates vs. pH for 
ND-COOH (•), ND-OH (■), and ND-NH2 (▲)...............................................71
Figure 4. A-C. Langmuir (solid red line) and Freundlich (blue dashed line) fits to 
experimental adsorption isotherms of A. ND-COOH, B. ND-OH, and 
C. ND-NH2. D. Overlay of Langmuir fits from A-C........................................ 74
Figure 5. A. Kl vs. Amax B. Separation factor Rl vs. Co ..................................................76
Figure 6. A-C. Plots of cumulative tiopronin release as a percentage of the initial
amount of adsorbed tiopronin vs. time for A. ND-COOH, B. ND-OH, and
C. ND-NH2 in pH 4.0 (•), 5.8 (■), 7.3 (▲), and 8.1 (▼) buffer.
D-E. Cumulative tiopronin release after 1 day and 12 days, expressed as
D. percentage of the initial amount of adsorbed tiopronin and E. mass of




Table 1. Treatment media compositions............................................................................13
Table 2. Effects of exposure to tBHP and treatment with MPG on viable, apoptotic,
and necrotic subpopulations.................................................................................23
Table 3. Effects of tBHP exposure and MPG treatment on percentage of ROS+ cells
in apoptotic and live cell populations.................................................................. 26
Table 4. Effects of exposure to tBHP and MPG on the percentage of MSR+ cells in
apoptotic and live cell populations...................................................................... 28
PAPER II
Table 1. Detector settings................................................................................................. 43
Table 2. Summary of linear regression............................................................................. 51
Table 3. Stability of derivatized samples.......................................................................... 52
Table 4. Precision, accuracy, and recovery......................................................................  53
Table 5. MPG and MPA concentration in Wistar rat tissues 40 min after
intraperitoneal administration of MPG................................................................ 54
PAPER III
Table 1. Parameters and Pearson’s correlation coefficient for Langmuir and
Freundlich curve fits to adsorption data.............................................................. 75







A549 Adenocarcinomic Human Alveolar Basal Epithelial Cell Line




FBS Fetal Bovine Serum
FL Fluorescence
FTIR Fourier Transform Infrared Spectroscopy
GSH Glutathione
HPLC High Performance Liquid Chromatography
MPA 2-Mercaptopropionic Acid; Thiolactic Acid
MPG 2-Mercaptopronyl Glycine; Tiopronin











R Pearson's Correlation Coefficient
ROS Reactive Oxygen Species
SAED Small-Area Electron Diffraction
SAUD Salt-Assisted Ultrasonic Deaggregation
SBB Serine Borate Buffer
SDS Sodium Dodecyl Sulfate
tBHP tert-Butylhydroperoxide
TCEP Tris(2-Carboxyethyl)Phosphine)
TEM Transmission Electron Microscopy
XRD X-Ray Diffraction
1. INTRODUCTION
1.1. GLOBAL HEALTH IMPACT OF CATARACTS
Cataracts are characterized by a cloudy opacification of the ocular lens that 
progressively worsens to the point of complete vision loss. They are also the leading 
cause of blindness worldwide.1 Currently, the only available treatment for patients with 
cataracts is surgical removal of the cataractous lens and subsequent implantation of an 
artificial lens. Although this procedure is routine and relatively safe, it is not without 
drawbacks. As with any surgery, there is a risk of serious complications such as capsular 
rupture, loss of vitreous, and endophthalmitis.2 In addition, artificial lenses lack several 
important properties of natural lenses. The natural lens is able to stretch, allowing for 
accommodation or focusing on objects or features at a variety of distances. Artificial 
lenses from cataract surgery do not recapitulate this ability. Furthermore, research 
conducted by Lim et al. suggests that the natural lens plays a significant role in 
maintaining ocular health.3 It serves as a reservoir for the vital antioxidant glutathione 
(GSH), protecting neighboring structures from oxidative damage. With this reservoir 
removed, patients may be at a greater risk of developing other oxidative stress-related eye 
disorders such as macular degeneration. Therefore, there is a high demand for non­
invasive pharmaceutical alternatives to surgery to treat, prevent, or delay cataract 
formation.
1.2. CATARACTOGENESIS AND AVENUES FOR TREATMENT
The lens contains highly ordered layers of tightly packed cells known as lens 
fibers. The refractive power and transparency of the lens is attributed to water-soluble
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proteins known as crystallins which compose more than 90% of the protein content of the 
lens.4, 5 Oxidative damage can disrupt the native structure of these proteins, resulting in 
aggregation and loss of transparency. Thus, cataracts are attributed to the aggregation of 
crystallins. The primary source of oxidative damage in cataracts is most likely ultraviolet 
radiation; however, other contributing sources of oxidative stress include injury, genetic 
mutation, and exposure to toxicants or ionizing radiation.
In order to maintain transparency, the nuclear portion of the lens forgoes light­
scattering organelles such as nuclei, mitochondria, and endoplasmic reticula.6 As a result, 
lens fiber cells are less metabolically active than most tissues, and once these cells 
mature, the crystallins are not replaced. Therefore, oxidative damage to crystallin proteins 
accumulates over a person’s lifetime, progressively worsening with age. It is well 
documented that damage to these proteins is correlated to their aggregation.7, 8 Oxidation 
of cysteine and methionine residues progressively increase with cataract severity until 
>90% of cysteine residues and 50% of methionine residues are oxidized.7 Oxidation of 
cysteine residues in crystallin proteins is noteworthy because it results in intra- and inter­
protein cross-linking, altering the native structure of the protein, decreasing the solubility 
and thus, lens transparency.
Crystallins rely heavily on endogenous antioxidants such as GSH to protect them 
from oxidative damage in order to preserve their normal structure and function.3, 8 9 
However, levels of these endogenous antioxidants decrease significantly with age,10, 11 
leaving the lens vulnerable to oxidative insult.12, 13 Indeed, reports have shown that more 
than 60% of GSH is depleted in cataractous lenses.8
Since loss of endogenous antioxidant defenses is so strongly correlated with the 
progression of age-related nuclear cataract, bolstering these defenses with exogenous 
antioxidants is one of the primary treatment strategies being explored for delaying 
cataract progression.
Supplementing GSH directly is impractical due to its low membrane permeability 
and enzymatic degradation; however, other thiol-containing antioxidants have shown 
some promise. Thiol antioxidants can scavenge ROS and undergo thiol-disulfide 
exchange with oxidized cysteine residues. Indeed, reports in the literature demonstrate 
that thiol antioxidants may prevent or ameliorate cataracts.14, 15
1.2.1. Tiopronin. Tiopronin, formally known as 2-mercaptopropionyl glycine 
(MPG), is an FDA-approved thiol antioxidant that is used clinically to treat cystinuria. 
Patients with cystinuria have high levels of cystine in their urine, resulting in cystine 
kidney stones. Tiopronin undergoes thiol-disulfide exchange with cystine to form 
tiopronin-cysteine, which is more urine-soluble. This thiol-disulfide exchange, in 
combination with the capacity for scavenging ROS, may be beneficial for protecting 
against oxidative insults and reducing crystallin protein disulfides in the lens.
In fact, MPG has demonstrated anticataract effects in various animal and cell 
models16-20 and even human cataract patients.21 Although these results are promising, the 
routes of administration used are impractical for human patients. When MPG is 
administered orally, very high doses are required for it to accumulate in the lens. This is 
attributed to the fact that the lens lacks a direct, dedicated blood supply. Maintaining such 
high doses can result in several systemic side effects.22, 23
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1.2.2. Eye Drops Are the Preferred Route of Administration. Eye drops offer 
several advantages over oral and other systemic routes of administration. They are easy to 
administer and allow for localized application to the target organ, circumventing the need 
for high systemic doses and reducing the risk and severity of side effects. However, this 
approach poses challenges as well. The eye has a number of anatomical and physiological 
barriers against foreign species, and the majority of the drug is blinked away or wasted in 
tears.24 The remaining drug must then penetrate the cornea and diffuse through the 
aqueous humor in sufficient concentrations to reach the lens. In order to achieve effective 
concentrations of MPG in the lens, it is necessary to prolong residence on the cornea.
1.2.3. Drug Delivery Vehicles Can Promote MPG Uptake and Efficacy. To 
increase drug residence time and penetration, drug delivery methods such as 
biocompatible polymers or gels have been explored. For example, a poloxamer gel-based 
drug delivery vehicle for MPG was studied in rodents.18 The drug delivery gel increased 
MPG residence time, allowing more the drug to penetrate the cornea, and thus delayed 
cataract formation significantly longer compared to MPG solution. Although they have 
generated a great deal of interest for ocular drug delivery,25-27 gels are not ideal agents for 
this purpose due to their instability under sterilization and storage conditions.28-30 In 
addition, as an antioxidant, MPG is prone to oxidation under these conditions. An ideal 
delivery platform for a thiol drug like MPG would prolong its retention on the ocular 
surface, augment its antioxidant properties, and protect it from premature degradation.
1.2.4. Nanodiamond Drug Delivery. Nanodiamond (ND) is a promising 
candidate for drug delivery due to its biocompatibility, physical properties, and 
customizability.31 Further, ND is chemically stable and does not degrade under harsh
sterilization conditions.32 Nanodiamonds are approximately spherical particles with a 
primary particle size of 4-6 nm, which results in specific surface areas in the range of 
300-500 m2/g for adsorption or chemical binding of drugs.33 Moreover, the surface of 
nanodiamond can be functionalized to suit a variety of applications.34 For example, 
carboxylated nanodiamond (ND-COOH) can be used for the delivery of positively 
charged chemotherapy drugs.35-40 The majority of the ND-COOH surface will be 
negatively charged at physiological pH (7.4) due to the deprotonation of the carboxylic 
acid groups. The positively charged chemotherapy drug tends to remain bound to the 
negatively charged ND-COOH due to electrostatic interactions. Upon reaching the acidic 
microenvironment surrounding tumor cells, however, the negative charge on the ND- 
COOH will become neutralized. With electrostatic interactions greatly reduced, the drug 
is readily desorbed in the tumor microenvironment.
In the case of ocular drug delivery, pH-triggered release is not a primary concern. 
Instead, it may be useful to engineer the nanodiamond surface to maximize interactions 
with the cornea in order to improve residence time and resist being blinked away. Other 
considerations include ND loading capacity, agglomeration, rate of release, toxicity 
limits, and impact on drug effectiveness. Nanodiamond may also be particularly 
advantageous for delivery of antioxidants because they can absorb UV light, thereby 
preventing premature degradation of the antioxidant drug.41 Even better, some studies 
have shown that ND may exhibit some level of intrinsic antioxidant activity.41, 42
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1.3. DEVELOPMENT AND EVALUATION OF ND:MPG FORMULATIONS
The studies reported in this dissertation reflect the foundational work necessary 
for evaluating the potential for MPG to protect against oxidative stress and to establish 
and evaluate the potential of ND as an MPG delivery vehicle for the prevention of 
cataract and other age-related eye disorders. This dissertation reports the following three 
studies in greater detail:
1. The potential of MPG to protect cells from oxidative damage was evaluated in an 
epithelial cell line commonly used for early drug screening.
2. A high-sensitivity method was developed for quantifying MPG and its metabolite, 
MPA, in ocular tissues. This is a necessary tool for determining the extent of 
MPG loading and release from ND, as well as its fate when administered to 
biological models.
3. The effect of ND surface chemistry on adsorption and release of MPG was 
determined. This information is important for informing the selection of surface 
functionality in the context of different applications. The results of this study can 
also be used to understand why one type of ND functionalization may be more or
less effective than another.
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ABSTRACT
Tiopronin (MPG) is a thiol antioxidant drug that has been explored as a treatment 
for various oxidative stress-related disorders. However, many of its antioxidant 
capabilities remain untested in well-validated cell models. To more thoroughly 
understand the action of this promising pharmaceutical compound against acute oxidative 
challenge, A549 human lung carcinoma cells were exposed to tert-butyl hydroperoxide 
(tBHP) and treated with MPG. Analyses of cell viability, intracellular glutathione (GSH) 
levels, and prevalence of reactive oxygen species (ROS) and mitochondrial superoxide 
were used to examine the effects of MPG on tBHP-challenged cells. MPG treatment 
suppressed intracellular ROS and mitochondrial superoxide and prevented tBHP-induced
GSH depletion and apoptosis. These results indicate that MPG is effective at preserving 
redox homeostasis against acute oxidative insult in A549 cells if present at sufficient 
concentrations during exposure to oxidants such as tBHP. The effects of treatment 
gleaned from this study can inform experimental design for future in vivo work on the 
therapeutic potential of MPG.




#-(2-mercaptopropionyl)glycine (MPG), or tiopronin, is low-molecular-weight 
thiol derivative of glycine that has been used to treat a variety of conditions. MPG was 
one of the first disease-modifying anti-rheumatic drugs [1-3], but it has been superseded 
by biologics and is now only applied in certain refractory cases [4,5]. MPG is the first- 
line treatment for cystinuria, in which it forms mixed disulfides that are up to 50 times 
more soluble than cystine, thus preventing the formation of cystine kidney stones [6,7]. 
While these applications fill important medicinal niches, the antioxidative properties of 
MPG have warranted its investigation for the treatment of more prevalent conditions. Its - 
SH moiety can reduce disulfide linkages between oxidized biothiols, like glutathione 
disulfide, restoring them to their native state [8,9]. In addition, MPG is regarded as an 
effective chelator of heavy metals such as mercury and copper. In silico models predict 
that formation of MPG-copper(II) complexes can reduce the rate constant of the first step 
in the Haber-Weiss reaction six-fold [10]. Because of these significant antioxidant
properties, MPG has been used to protect against chemotherapy-induced nephro- and 
hepatotoxicity [11,12] , radiation poisoning [13], and ischemia-reperfusion injury to 
cardiac and lung tissue [12,14]. Further, MPG may be able to counteract oxidative 
processes that lead to lens opacification in senile cataracts [15-21]. MPG offers several 
advantages over similar drugs, including a more favorable side effect profile than D- 
penicillamine [4] and better bioavailability than ^-acetylcysteine [22,23]. Moreover, 
MPG’s primary metabolite, 2-mercaptopropionic acid, is also a potent radical scavenger 
[24]. With the growing impetus to repurpose pharmaceuticals, the medical community 
stands to gain potential treatments and greater understanding of oxidative stress-related 
conditions from renewed interest in MPG. However, its action against acute exogenous 
oxidative insult in cell models has not been thoroughly characterized.
To bridge this gap in understanding, well-established cell lines such as A549 are 
commonly used to study the action of drugs in vitro [25-27]. As a pulmonary epithelial 
cell line, it is often employed to study effects of inhalation exposure to environmental 
contaminants, in which oxidative stress plays a key role [28]. Further, it is recognized as 
a useful model for early-stage biopharmaceutical research, including studies of drug 
metabolism and cytotoxicity [29,30]. A well-validated oxidant is another integral 
component of an appropriate system for testing an antioxidant drug. For in vitro studies, 
tert-butyl hydroperoxide (tBHP) is more reliable than hydrogen peroxide, as tBHP has 
demonstrated more consistent ability to induce oxidative stress than H2O2 [31,32]. This 
may be attributed to the greater stability of the tert-butoxyl radical in aqueous solution 
[33] and fewer enzymes dedicated to its detoxification (e.g., glutathione peroxidase only 
versus glutathione peroxidase and catalase for H2O2) [25]. Further, decomposition of
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tBHP and downstream action of its byproducts may recapitulate many of the oxidative 
mechanisms observed in vivo, including lipid peroxidation, DNA damage, depletion of 
GSH and protein thiols, alteration of intracellular calcium homeostasis, and apoptosis 
[25,34]. For these reasons, tBHP is better suited for probing the intracellular action of 
MPG. Therefore, we utilized tBHP to rapidly induce severe oxidative damage in A549 
cells and administered MPG simultaneously to test the action of MPG against acute 
oxidative insult. To observe and characterize the effects of MPG under these conditions, 
we examined cell viability, intracellular GSH levels, and distribution of cells in apoptotic 
and non-apoptotic populations exhibiting intracellular ROS and mitochondrial 
superoxide.
10
2. MATERIALS AND METHODS
2.1. CHEMICALS AND REAGENTS
MPG, tBHP solution, Tris-HCl, L-serine, boric acid, 
diethylenetriaminepentaacetic acid, and A-(1-pyrenyl)maleimide were purchased from 
MilliporeSigma (St. Louis, MO). MPG stock solutions were prepared in sterile Type 1 
water prepared in-house with a Millipore Simplicity 185 System. Glacial acetic acid, o- 
phosphoric acid, and high-performance liquid chromatography (HPLC) grade solvents 
were purchased from Fisher Scientific (Fair Lawn, NJ).
11
2.2. CELL CULTURE AND PRELIMINARY EXPERIMENTS
A549 (human lung carcinoma) cells were kindly provided by Dr. Yue-Wern 
Huang from the Biological Sciences Department at Missouri University of Science and 
Technology.
Cells were grown in phenol-red-free DMEM/F12 medium (Thermo Fisher 
Scientific, Waltham, MA) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) and 1% penicillin/streptomycin/amphotericin B (Thermo Fisher Scientific) in a 
humidified incubator with 5% CO2/95% air at 37°C. Serum- and growth-factor-free 
medium was used for all MPG and tBHP experiments, instead of the fully supplemented 
media described above. Cells were passaged twice per week at a subcultivation ratio of 
1:3. All experiments were performed using cells between passage 10 and 30.
To determine an appropriate concentration of tBHP for use in this study, A549 
cells were seeded in multiple-well plates and divided into groups. Each group was 
incubated for 3 hours with a different concentration of tBHP in serum-free media, 
ranging from 0.25 mM to 4.0 mM. Cytotoxicity of tBHP in each group was assessed via 
MTT assay as described below to identify the range of concentrations at which cell 
viability was reduced to 50-60% of the control, which was shown to be 0.5 to 1.0 mM. 
To determine whether cells received sufficient oxidative insult, intracellular GSH levels 
were measured in groups treated with tBHP concentrations ranging from 0.4 to 0.8 mM 
for 3 hours. Based on these preliminary experiments, a concentration of 0.6 mM tBHP 
was selected for use in the remaining experiments.
Next, an appropriate concentration of MPG for treating tBHP-exposed cells was 
selected. To determine whether MPG alone had any adverse effect on cell viability,
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A549 cells were seeded in multiple-well plates and divided into groups. Each group was 
incubated for 3 hours with different concentrations of MPG in serum-free media, ranging 
from 0.08 mM to 10 mM, and MPG was not found to significantly affect cell viability at 
these concentrations (data not shown). To determine an appropriate concentration for use 
in tBHP-exposed cells, a similar experiment was conducted with the simultaneous 
addition of 0.6 mM tBHP and either 1.0, 1.5, 2.5, or 5.0 mM MPG for 3 hours. Cell 
viability and GSH levels in respective groups indicated that 5.0 mM MPG provided 
optimal protection against tBHP. Based on these preliminary experiments, 5.0 mM MPG 
and 0.6 mM tBHP were used in subsequent experiments to determine the effects of MPG 
on oxidative stress induced by tBHP.
2.3. EXPERIMENTAL DESIGN
The A549 cells were grown in complete media and allowed to proliferate for 24 
hours. The cells were divided into 4 treatment groups: control, MPG only, tBHP only, 
and MPG + tBHP. After the 24-hour proliferation time, the complete medium was 
removed and replaced with the treatment medium associated with the corresponding 
treatment group (Table 1). The treatment media were supplemented with tBHP or MPG 
immediately prior to each experiment from freshly prepared concentrated stock solutions. 
The cells were allowed to incubate in the treatment media for 3 hours. After this time, the 
treatment media were removed. Cell viability and oxidative stress parameters including 
GSH and flow cytometric analysis of ROS and mitochondrial superoxide were 
determined after treatment as described in the following sections.
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Table 1. Treatment media compositions
Group Treatm ent m edium
Control M edium
MPG only M edium  + 5 mM MPG
tBHP only M edium  + 0.6 mM tBHP
MPG + tBHP M edium  + 5 mM MPG + 0.6 mM tBHP
2.4. CELL VIABILITY
Cells were seeded at a density of 2 x 104 cells/well in 96-well plates and allowed 
to adhere and proliferate for 24 hours. Then, cells were divided into groups and treated as 
described in the experimental design. After the treatment, the treatment media were 
replaced with fresh F12 medium, and cell viability was determined using the Vybrant 
MTT Cell Proliferation Assay Kit (Invitrogen, Carlsbad, CA) as described by the 
manufacture. The MTT assay is a colorimetric assay through which cell viability is 
estimated by conversion of the water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
dimethyltetrazolium bromide) to an insoluble formazan by viable cells. The formazan is 
then solubilized by sodium dodecyl sulfate (SDS), and the concentration is determined by 
measuring absorbance at 570 nm using a microplate reader (Fluor Star Optima, BMG, 
Labtech). Cell viability was expressed as the absorbance by the contents of a given well 
divided by that of the mean absorbance measured for the control group.
2.5. QUANTIFICATION OF INTRACELLULAR GSH LEVEL
Cells were seeded at a density of 6 x 105 cells/well in 6-well plates 24 hours 
before the experimental treatment. Cells were treated as described in the experimental 
design. Following treatment, the cells were harvested with trypsin/EDTA and collected in
1.5 mL RINO tubes (Next Advance, Troy, NY, USA). The cell suspensions were 
centrifuged at 500 x g  for 10 min at 4°C. The supernatants were removed, and the cells 
were resuspended in 1 mL aliquots of PBS to rinse away remaining media and 
extracellular GSH. This centrifugation and rinsing process was repeated. After rinsing, 
the cells were centrifuged again at 500 x g  and resuspended in 250 pL aliquots of chilled 
serine-borate buffer (100 mM Tris-HCl, 5 mM L-serine, 10 mM boric acid, 1 mM 
diethylenetriaminepentaacetic acid, pH 7.0). A 100 pL scoop was used to add about 100 
pL of zirconium oxide beads (0.5 mm diameter, Next Advance) to each of the cell 
suspensions. The cells were homogenized using a Bullet Blender Storm tissue 
homogenizer (Next Advance) at speed “8” for 3 min. After homogenization, the cells 
were immediately centrifuged at 5000 x g  for 5 min at 4°C. Then, 100 pL aliquots of 
supernatant were collected from each RINO tube for analysis of GSH and total protein 
content.
Intracellular GSH levels were determined by HPLC with pre-column 
derivatization and fluorescence detection, according to a method developed in our 
laboratory [35]. Briefly, 50-pL aliquots of cell homogenate were diluted with 200 pL of 
serine-borate buffer. The samples were derivatized by the addition of 750 pL of N-(1- 
pyrenyl)maleimide (1 mM in acetonitrile). The samples were mixed and allowed to react 
for 5 min. After this time, 10 pL of 2 M HCl were added to stabilize the fluorescent 
adducts. Samples were filtered with 0.45 pm nylon membrane filters. Samples were 
injected onto an Orochem (Naperville, IL, USA) Reliasil ODS-1 column (4.6 mm i.d. x 
250 mm) and eluted with a mobile phase consisting of 70:30 (v/v) acetonitrile-water with 
1 mL/L of o-phosphoric acid and 1 mL/L of glacial acetic acid, delivered at a flow rate of
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1 mL/min. GSH levels were determined by using a calibration curve prepared from 
standards processed in parallel with the unknown samples.
The GSH levels were normalized to the amount of total protein present in each 
sample. Total protein levels were estimated using the Coomassie dye-binding method 
described by Bradford [36]. Bradford dye reagent (Bio-Rad, Hercules, CA, USA) was 
diluted five-fold in serine borate buffer, and 1 mL aliquots of the diluted dye reagent 
were added to 20 pL of diluted cell homogenate in cuvettes. The samples were left to 
incubate at room temperature for at least 5 min. The absorbance of 595 nm light was 
correlated to the total protein concentration using a calibration curve. Albumin from 
bovine serum was used to make calibration standards to estimate the protein content in 
the cell homogenates.
To account for differences in live cell populations between treatment groups,
GSH levels were reported in nanomoles of GSH per milligram of protein (nmol/mg).
2.6. FLOW CYTOMETRY ANALYSIS OF APOPTOTIC CELLS AND 
INTRACELLULAR ROS MEASUREMENT
Intracellular ROS content was measured using the carboxy derivative of 
fluorescein, carboxy-HsDCFDA (6-carboxy-2’,7’-dichlorofluorescein diacetate, 
Molecular Probes, Invitrogen), due to its additional negative charges that enhance cellular 
retention [37]. Flow cytometry (BD Accuri C6, BD Biosciences, Ann Arbor, MI) was 
used to assess the distribution of cells that contained ROS (ROS+ cells) within apoptotic 
and non-apoptotic cell populations. Cells were seeded on 24-well plates (Corning) at a 
density of 2 x 105 cells/well, grown over 24 hours, divided into groups and dosed as 
described previously. Trypsinized cells were washed with PBS and re-suspended in 250
15
gL of PBS containing 10 gM carboxy-H^DCFDA. After incubation for 30 minutes at 
37°C, the cells were washed with annexin V binding buffer and stained with 7-AAD (7- 
aminoactinomycin D, BD Pharmingen) and Annexin V Alexa Fluor 647 Conjugate 
(Invitrogen) for 15 minutes at room temperature in the dark. The FL-1 channel (Xex = 488 
nm and Xem = 533 nm) was used for carboxy-H2DCFDA, and the FL-3 channel (Xex = 533 
nm and Xem = 670 nm) was used for 7-AAD. Annexin V Alexa Fluor 647 fluorescence 
was measured using the FL-4 channel (Xex = 640 nm and Xem = 675 nm). Debris were 
excluded by forward vs. side scatter gating. Results are reported as percent of total cell 
population.
2.7. FLOW CYTOMETRY DETERMINATION OF MITOCHONDRIAL 
SUPEROXIDE
MitoSOX Red mitochondrial superoxide indicator (MSR) is a fluorogenic dye for 
selective detection of superoxide in mitochondria of live cells (Molecular Probes,
Eugene, OR). MSR is a dihydroethidium dye with a lipophilic, positively-charged side- 
chain for targeted absorption by the mitochondria. Upon oxidation by superoxide, the dye 
exhibits red fluorescence [38]. For analysis of superoxide generated in mitochondria, 
cells were grown in the same conditions as for the measurement of ROS content via flow 
cytometer. Harvested cells were washed with PBS and re-suspended in 250 gL of PBS 
containing 5 gM MSR. Cells were incubated for 30 minutes at 37°C. After incubation 
with MSR, LIVE/DEAD Fixable Green Dye (Molecular Probes, Eugene, OR) was added 
directly to each sample according to the manufacture’s recommendation. Cells were 
incubated for an additional 15 minutes at room temperature. The final stain, Annexin V 
Alexa Fluor 647 Conjugate, was added after washing cells with annexin V buffer. Cells
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were analyzed by flow cytometry using the FL-1 channel (kex = 488 nm and Xem = 533 
nm) for LIVE/DEAD Fixable Green, the FL-2 channel for MSR (kex = 488 nm and kem = 
585 nm), and the FL-4 channel for Annexin-V Alexa Fluor 647 (kex = 640 nm and kex = 
675 nm). Results are reported as percent of total cell population with MSR fluorescence 
(MSR+) cells in apoptotic and viable populations in each treatment group. Debris were 
excluded by forward vs. side scatter gating.
2.8. STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism 8 software (GraphPad, 
San Diego, CA, USA). All values were reported as mean ± standard deviation of at least 
three separate experiments, with n = 3-16. Statistical significance was performed by two­
way analysis of variance (ANOVA) for flow cytometry experiments and one-way 
ANOVA for all other experiments. ANOVA was followed by Tukey’s or Dunnette’s 
multiple comparison tests.
3. RESULTS AND DISCUSSION
3.1. SELECTION OF DOSING CONCENTRATIONS
To determine an appropriate concentration of tBHP for inducing oxidative stress, 
cell viability and GSH levels were determined following exposure to varied 
concentrations of tBHP. GSH, y-glutamyl-cysteinyl-glycine, is the most abundant non­
protein thiol in the body and an essential endogenous antioxidant. It plays a vital role in 
reduction and detoxification of ROS, including peroxides like tBHP and is therefore 
crucial to the maintenance of redox homeostasis. Increase in oxidants can upset this
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delicate balance, leading to the oxidative modification of critical cellular components, 
dysfunction, and ultimately apoptosis. The effects of increasing fBHP concentrations on 
cell viability and GSH levels are reported in Figure 1. Concentrations from 0.25 mM to 
4.0 mM significantly decreased cell viability in a dose-dependent manner. The effect of 
tBHP concentration on GSH levels and cell morphology were also considered for 
selection of an appropriate concentration of fBHP for subsequent experiments. tBHP 
concentrations from 0.4 mM to 0.8 mM resulted in a statistically significant decrease in 
levels of intracellular GSH, which correlates with the dose-dependent decrease in cell 
viability.
Figure 1. A. Plot of cell viability vs. fBHP concentration. The height of the columns 
indicates the mean viability from 9 experiments. Error bars indicate standard deviation. 
B. Plot of intracellular GSH concentration vs. fBHP concentration. The height of the 
columns represents the mean of 3 experiments. Error bars indicate standard deviation. 
****p < 0.0001 compared to control. ***p < 0.001 compared to control. *p < 0.05
compared to control.
Upon comparing the effects of tBHP on GSH levels and cell morphology, it was 
noted that at 0.6 mM fBHP, GSH had decreased by approximately 50%, but at 0.8 mM,
cells lost adhesion, which interfered with analysis and weakened integrity of the model 
overall. A tBHP concentration of 0.6 mM struck the best balance between oxidative 
damage and maintenance of normal cell morphology. Therefore, 0.6 mM tBHP was 
selected for subsequent experiments. Although this tBHP concentration is relatively high, 
the A549 cell line is reportedly resistant to oxidative insult [39].
In the next set of experiments, a variety of MPG concentrations from 1.0 to 5.0 
mM were tested in different groups to determine the appropriate concentration for 
protection against oxidative stress induced by 0.6 mM tBHP. Intracellular GSH levels 




Figure 2. Plot of intracellular GSH concentration vs. dosing concentration of MPG. The 
height of the columns represents the mean of 3 experiments. Error bars indicate standard 
deviation. ****p < 0.0001 compared to tBHP only. **p < 0.01 compared to tBHP only.
Concentrations ranging from 1.0 mM to 5.0 mM MPG afforded significant 
improvement in GSH levels compared to untreated, tBHP-exposed cells, but cells treated
with 5.0 mM MPG exhibited the highest GSH levels. Since preliminary experiments 
showed concentrations of MPG up to 10 mM to be nontoxic to A549 cells, treatment with 
5.0 mM MPG was deemed an appropriate treatment for tBHP-induced oxidative stress 
for the remainder of the study.
3.2. EFFECT OF MPG ON INTRACELLULAR GSH IN OXIDATIVELY 
CHALLENGED A549 CELLS
To confirm the effects of 5.0 mM MPG on intracellular GSH levels in A549 cells, 
the cells were divided into groups as discussed in the experimental design and seeded as 
described earlier. The results of the intracellular GSH analyses are reported in Figure 
3A.The data were normalized by the amount of protein present in each sample to account 
for differences in viable cell count. Exposure to tBHP without MPG resulted in a 
significant decrease in intracellular GSH levels compared to the control group. Cells 
treated with MPG, either with or without tBHP, had GSH levels that were not 
significantly different from that of the control group. Therefore, administration of 5.0 
mM MPG with 0.6 mM tBHP was effective for preventing loss of free GSH, and MPG 
alone does not increase GSH levels beyond that of the control group. These results are 
consistent with the hypothesis that GSH levels are spared by the action of MPG as 
opposed to being directly increased.
3.3. EFFECT OF MPG ON VIABILITY OF OXIDATIVELY CHALLENGED 
A549 CELLS
To determine whether MPG could protect cells from tBHP-induced loss of 
viability, the MTT assay was used as an indicator of cellular metabolism. This assay is
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based on the ability of metabolically active cells to reduce MTT to an insoluble, colored 
formazan product that can be measured spectrophotometrically. Cell viability for each 
treatment group is reported in Figure 3B as a percentage of absorbance at 570 nm 
compared to that of the control group. As was the case in our preliminary studies, cells 
exposed to 0.6 mM fBHP without MPG exhibited significantly less viability compared to 
the cells in the control group, and the viability of cells in the MPG + tBHP group was 
statistically similar to that of the cells in the control group. Treatment of A549 with 5 
mM MPG alone also did not increase or decrease cell viability.
Figure 3. A. Plot of treatment vs. intracellular GSH concentration. The height of the 
columns indicates the mean of 9 experiments and error bars represent the standard 
deviation. B. Plot of treatment vs. cell viability. The height of the columns indicates the 
mean of 14 experiments, and error bars represent the standard deviation. ****p < 0.0001
compared to control.
This trend closely parallels that of intracellular GSH levels and makes sense in the 
context of the biochemistry behind the MTT assay. The reduction of MTT to formazan is 
sensitive to decreases in available NADPH [40]. The NADPH cofactor serves as the 
reductant for a host of anabolic processes, as well as the reduction of oxidized glutathione
to its active reduced form. Thus, gross metabolic dysfunction resulting from tBHP is 
manifested in the inability of oxidatively damaged, dying cells to reduce MTT and 
regenerate GSH from its oxidized form. In contrast, cells treated with MPG exhibited 
marked improvement in both cell viability and GSH levels. We hypothesize that this is 
due to the following effects of MPG. As a thiol antioxidant that can directly reduce 
tBHP-derived ROS, MPG can spare GSH from oxidation, leaving cellular GSH stores 
largely intact. In preventing oxidation of GSH, MPG also preserves NADPH for use in 
reductive biosynthesis and conversion of MTT to formazan.
3.4. EFFECT OF TREATMENT ON APOPTOTIC AND NECROTIC CELL 
POPULATIONS
Flow cytometry is a well-established technology that has been widely used for 
measuring intrinsic and extrinsic properties of fluorescently labeled cells. This property 
permits the identification of subpopulations within the sample, and quantification of cell 
populations through selective fluorescence labeling. While microplate readers provide 
rapid data acquisition, the accuracy of the measurements suffers since the end value 
corresponds to the average fluorescence per well while flow cytometry provides 
information at the single-cell level. For this analysis, cells were labeled with 7-AAD and 
Annexin V Alexa 647 to investigate live, necrotic, and apoptotic cell populations. Live 
cells are not typically permeable to 7-AAD. Cells in early apoptotic stages bind only to 
Annexin V Alexa 647, while cells in late apoptotic stages bind to both Annexin V Alexa
22
647 and 7-AAD. Necrotic cells bind to 7-AAD, but not Annexin V Alexa 647.
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Representative dot-plots from the flow cytometry analysis are provided in Figure
4. The mean distributions of cells among apoptotic, necrotic, and viable cell populations 












































Figure 4. Representative dot-plots from flow cytometry analysis of apoptotic cells. 
Shown are plots of fluorescence associated with Annexin V Alexa 647 (FL-4) vs. 7-AAD
(FL-3) from different treatment groups.
Table 2. Effects of exposure to tBHP and treatment with MPG on viable, apoptotic, and
necrotic subpopulations.
Subpopulation
Cells in subpopulation (% of total cell population)t
Control MPG only tBHP only MPG + tBHP
Early apoptotic 3.1 ± 1.3 2.6 ± 0.9 4.3 ± 1.3 3.0 ± 0.7
Late apoptotic 2.3 ± 0.4**** 2.3 ± 0.6**** 11.2 ± 4.7 2.9 ± 0.7****
Viable 94.3 ± 1.2**** 94.5 ± 0.8**** 81.7 ± 8.2 93.5 ± 1.0****
Necrotic 0.4 ± 0.3 0.6 ± 0.4 2.8 ± 2.6 0.6 ± 0.6
t Mean ± SD of 8 experiments.
**** p  < 0.0001, compared to tBHP only group.
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As observed previously, the percentage of viable cells in the MPG + tBHP treated 
group was significantly higher than in the tBHP group. Further, the percentage of viable 
cells in the MPG + tBHP group was statistically similar to the percentages in the MPG 
only group and the control group. The same trend was observed within late apoptotic 
subpopulations. Exposure to 0.6 mM tBHP without MPG resulted in an elevated 
proportion of cells exhibiting fluoresence associated with binding of 7-AAD and Annexin 
V Alexa 647. However, cells treated with MPG, alone or with tBHP, were not 
significantly different from the control cells. These data suggest that exposure to 0.6 mM 
tBHP without MPG results in oxidative stress-associated apoptosis while treatment with 
MPG mitigates the damage that triggers this process. Although there does not appear to 
be a significant difference in the proportion of cells occupying the necrotic quadrant 
among groups, this can be attributed to the fact that cellular debris are excluded prior to 
quantitation. There was a significantly lower number of cells available for counting in the 
tBHP only group, compared to the other groups. This loss of countable cells is indicative 
of membrane disintegration associated with tBHP exposure.
3.5. DISTRIBUTION OF CELLS WITH ROS PRESENT IN APOPTOTIC AND 
NON-APTOPTOTIC SUBPOPULATIONS
Based on the results of GSH and MTT assays, we hypothesized that MPG 
prevents cell death by protecting cells from oxidative damage, and therefore, we would 
expect to see significantly higher levels of ROS in cells in the tBHP only group than in 
the other groups. To estimate the levels of intracellular ROS, carboxy-HsDCFDA was 
used to identify ROS+ cells. Carboxy-HsDCFDA is a membrane-permeable derivative of 
the fluorescent probe fluorescein. Upon cleavage of its acetate groups and oxidation by
intracellular ROS, the dye becomes trapped within the cell and fluoresces green [38]. 
Cells were co-stained with two other fluorescent probes, Annexin V Alexa Fluor 647 
conjugate and 7-AAD, and then the cells were subjected to flow cytometric analysis. 
Representative dot plots are shown in Figure 5. In this study, co-staining was used to 
differentiate between apoptotic and non-apoptotic cell subpopulations and to exclude 
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Figure 5. Representative dot-plots from flow cytometry analysis of ROS in apoptotic and 
live subpopulations. The cells were gated excluding debris. Viable cells were gated by 
exclusion of 7-AAD+ cells (FL-3) on 2D plots (live gate). The quantification of ROS was 
done using 2D plots of Carboxy-H^DCFDA (FL-1) vs. Annexin V Alexa 647 (FL-4).
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Table 3. Effects of tBHP exposure and MPG treatment on percentage of ROS+ cells in
apoptotic and live cell populations.
Subpopulation Cells in subpopulation (% of total cell population)*Control MPG only tBHP only MPG + tBHP
ROS in apoptotic cells 1.7 ± 0.9 1.3 ± 0.8 3.6 ± 1.4 1.6 ± 0.6
ROS in live cells 1.5 ± 0.5**** 2 2  + 1 1  **** 22.5 ± 2.3 4.2 ± 1.0****
Total ROS 3.3 ± 0.9**** 3.5 ± 1.6**** 26.1 ± 2.7 5.8 ± 1.1****
t Mean ± SD of 8 experiments.
**** p < 0.0001, compared to tBHP only group.
The results of the analysis (summarized in Table 3) indicate that there were 
indeed significantly more ROS detected in live cells treated with tBHP only than in any 
of the other groups. This correlates well with the GSH and cell viability results and is 
consistent with the supposition that MPG protects cells from oxidative stress by reducing 
ROS associated with exposure to tBHP.
Numbers of ROS+ cells in apoptotic subpopulations were low in all groups, and 
differences between these subpopulations did not reach statistical significance. Small 
subpopulations of apoptotic, ROS+ cells may be due to the exclusion of late-stage 
apoptotic and necrotic cells by gating out 7-AAD-fluorescent cells. As shown in Table 2, 
the tBHP only group had a significantly higher subpopulation of late-stage apoptotic 
cells, suggesting that tBHP-induces rapid progression to late-stage apoptosis or secondary 
necrosis [41]. Since these cells exhibit 7-AAD fluorescence, they would have been gated 
out and thereby excluded from the study [42].
3.6. DISTRIBUTION OF SUPEROXIDE PRESENT IN MITOCHONDRIA OF 
APOPTOTIC AND NON-APOPTOTIC POPULATIONS
Low levels of superoxide in mitochondria are generated as a result of normal
metabolic processes, but excessive amounts are associated with electron-transport chain
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dysfunction [43]. This can lead to decreased ATP production, loss of mitochondrial 
membrane potential, and ultimately opening of the mitochondrial permeability transition 
pore and initiation of the apoptotic cascade [44,45]. In this way, mitochondria are highly 
sensitive to fluctuations in redox status, [44] and may serve as a predictor of apoptotic 
response to acute oxidative insult [45].
MSR, a mitochondria-permeable dye, fluoresces upon oxidation by superoxide. 
Similar to the flow cytometric analysis of ROS+ cells, MSR was used to determine the 
percentage of cells with superoxide present in the mitochondria. Representative dot plots 
are shown in Figure 6.
Figure 6. Representative dot-plots of from flow cytometry analysis of superoxide in 
mitochondria. The total cells were gated excluding debris. Viable cells were gated by 
exclusion of Live/Dead green+ cells (FL-1) on 2D plots (live gate). The quantification of 
MSR+ cells was done using 2D plots of MSR (FL-2) vs. Annexin V Alexa 647 (FL-4).
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Table 4 shows the quantitative results as mean percentages of the total cell 
population. The percentage of MSR+ live cells in the MPG + tBHP group was 
significantly decreased compared to that in the tBHP only group. This indicates that MPG 
was able to preserve mitochondrial redox status. In light of the cell viability and GSH 
results, it may be the case that MPG prevents downstream release of mitochondria- 
derived ROS into the cell and halts progression towards apoptosis.
Table 4. Effects of exposure to tBHP and MPG on the percentage of MSR+ cells in
apoptotic and live cell populations.
Subpopulation
Cells in subpopulation  (% of total cell p o p u la tio n ^
Control M PG only tB H P only M PG + tBH P
M SR+ in ap op to tic cells 2.1 ± 0.5 2.0 ± 0.4 3.9 ± 1.3 2.3 ± 0.5
M SR+ in live cells 1.2 ± 0.4**** 1.3 ± 0.3**** 24.3 ± 3.2 8 .6  ± 1 .9 ****
Total M SR+ cells 3.2 ± 0.8**** 3.5 ± 0.5**** 28.2 ± 3.5 10.9 ± 2.2****
t Mean ± SD of 8 experiments.
**** p  < 0.0001, compared to tBHP only group.
4. CONCLUSIONS
In this study, tBHP was used to induce oxidative stress in A549 cells. Cells 
exposed to 0.6 mM tBHP without MPG showed elevated levels of intracellular ROS, 
mitochondrial superoxide, and cell death while also showing reduced levels of the vital 
antioxidant GSH and reduced cell viability. When 5.0 mM MPG was present along with 
0.6 mM tBHP, normal levels of these oxidative stress parameters were maintained. It is 
likely that MPG is interacting as a direct ROS scavenger, and the results obtained through 
this study suggest that if MPG is present in sufficiently high concentrations during an 
oxidative insult, it can be highly effective at preventing the ensuing damage. It is
probable that the MPG reacts directly with tBHP in the treatment medium, reducing it 
and its oxidative byproducts before they can cause significant damage to the cells. This 
action is desirable for treatment applications which demand protection against acute 
oxidative insult such as radioprotection, but it is important to consider the dosing 
conditions and timing since biological systems are inherently dynamic. This in vitro 
system lacks many of the complexities of in vivo models and is therefore subject to some 
limitations. Due to the robust nature of this lung carcinoma cell line, a relatively high 
dose of tBHP was required to model acute oxidative stress. Despite the popularity of this 
approach, it may not directly translate to in vivo systems. Thus, the results of this study 
warrant further investigation in more representative models, such as primary cell cultures 
and eventually animal studies.
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Tiopronin, formally 2-mercaptopropionylglycine (MPG), is currently prescribed 
to treat cystinuria and rheumatoid arthritis, and its antioxidant properties have led to its 
investigation as a treatment for cataracts, a condition in which oxidative stress is strongly 
implicated. To study its accumulation in the eye, a reliable, isocratic HPLC method was 
developed for the determination of MPG and its primary metabolite 2-mercaptopropionic 
acid (MPA) in plasma and relevant ocular tissues. This method utilizes pre-column 
derivatization and fluorescence detection. The 3.5 min separation enables high- 
throughput analysis, and validation experiments demonstrated that this method is suitable 
for evaluating ocular accumulation of MPG and MPA at concentrations as low as 66 and 
33 nM, respectively. Excellent linearity was achieved over the working concentration 
range with R2 > 0.997. Extraction recovery was reproducible within each matrix and
exceeded 97%. Accuracy was within 13.3% relative error, and intra- and inter-day 
precisions were within 6% CV and 7% CV, respectively. Sample stability was 
demonstrated under various storage conditions, and the use of an internal standard 
conferred exceptional ruggedness. This method has been successfully applied for the 
determination of MPG and MPA in plasma, cornea, lens and retina following 
intraperitoneal administration of the drug in Wistar rats.
1. INTRODUCTION
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MPG is a small-molecular weight synthetic aminothiol. It is also known by the 
generic name tiopronin. It is primarily used to treat cystinuria and rheumatoid 
arthritis.(Carlsson, Denneberg, Emanuelsson, Kagedal, & Lindgren, 1993) Its thiol 
moiety confers antioxidant properties such as the ability to scavenge free radicals 
(Castaneda-Arriaga, Vivier-Bunge, & Raul Alvarez-Idaboy, 2016) and undergo thiol 
disulfide exchange.(Lindell, Denneberg, & Jeppsson, 1995) It has also been investigated 
as a potential treatment for cataracts, (Ichikawa et al., 1980; Jiang, Sun, Shen, Wang, & 
Wang, 2009) in which oxidative stress has been strongly implicated.(Lou & Dickerson, 
1992; Truscott, 2005)
Although oral administration of MPG is most commonly used for cystinuria or 
rheumatoid arthritis patients (Carlsson et al., 1993), it is not an effective route for 
achieving appreciable concentrations of the drug in ocular tissues, especially the lens 
which lacks dedicated vasculature. Local, topical administration in the form of eye drops 
may allow for greater accumulation of the drug at its proposed site of action with lower
dosages and fewer side-effects, but only if sufficient concentrations can be achieved in 
the surrounding tissues to allow for diffusion or transport into the lens.Jarvinen,
Jarvinen, & Urtti, 1995) Unfortunately, rapid elimination in tear fluid and numerous 
anatomical barriers prevent accumulation of MPG in the lens when instilled as eye drops. 
Drug delivery vehicles may be able to overcome this obstacle, (Abdelkader, Alany, & 
Pierscionek, 2015; Jiang et al., 2009) but evaluating their efficacy for this application 
poses several key challenges. As shown in Figure 1, MPG is quickly metabolized to 2- 
mercaptopropionic acid (MPA) in plasma.(Hercelin et al., 1992)
37
In addition, preliminary experiments in our lab suggest that MPA itself is a potent 
antioxidant, and simply measuring ocular tissue levels of MPG alone provides an 
incomplete picture of its fate and distribution after administration. An ideal method
would be able to simultaneously determine levels of MPG and its major metabolite, 
MPA.(Hercelin et al., 1992) In addition, a highly sensitive and specific method is 
necessary when working with very limited sample quantities and highly complex 
biological matrices such as rodent cornea or retina (Dalle-Donne & Rossi, 2009).
If the method is to be used for such analyses, validation in the matrices of interest 
is also important. In this case, the cornea, lens, and retina are of primary interest. The 
cornea is the foremost obstacle to ocular drug penetration, and understanding the drug’s 
interaction with this tissue may provide key insights for improving its ability to mediate 
effects in more posterior structures such as the lens.(Jarvinen et al., 1995) As cataracts 
are the result of oxidative damage to crystallin proteins in the lens, this tissue is the 
proposed primary site of action for MPG. Additionally, the lens serves as an antioxidant 
reservoir, (Lim, Umapathy, Grey, Vaghefi, & Donaldson, 2017) and applying MPG may 
help to restore redox balance, thereby inhibiting processes leading to opacification. The 
retina is highly metabolically active and therefore sensitive to disruptions to ocular redox 
balance. In addition, its proximity to the ocular blood supply can provide additional 
information regarding influx and elimination of MPG and MPA. Finally, because a large 
proportion of any drug instilled in eye drop form is eliminated by tear fluid and passes 
into the bloodstream, (Jarvinen et al., 1995) plasma levels of MPG and MPA are also of 
interest for understanding the ocular uptake of this drug. Finally, practical considerations 
such as ease of implementation and sample processing should be taken into consideration 
for experiments involving time-sensitive materials, such as biological tissues and drugs 
with labile thiol functional groups. In these cases, robust methods that offer rapid and
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convenient quantification of drug concentration are preferred for high-throughput routine 
analyses.(McMenamin, Himmelfarb, & Nolin, 2009)
Other methods exist for determination of MPG in tissues.(Dalle-Donne & Rossi, 
2009) While most methods employ HPLC separation, detection methods vary. Some rely 
on UV detection, which can suffer from limited sensitivity and interference in complex 
matrices. Others employ mass spectrometric detection, which may not be accessible or 
practical in many cases. Fluorescence detection, on the other hand, is both highly 
sensitive and economical, making it the most popular method for detection of thiol 
compounds. (McMenamin et al., 2009) Indeed, our group has previously demonstrated 
successful quantification of biologically relevant thiols, including MPG, via 
derivatization with maleimide dyes and HPLC separation of the fluorescent adducts. 
(Penugonda, Wu, Mare, & Ercal, 2004; Ridnour, Winters, Ercal, & Spitz, 1999; Wu, 
Goldstein, Adams, Matthews, & Ercal, 2006) However, the method described here offers 
several significant improvements in terms of robustness, convenience, precision, 
accuracy, and analysis time. It also eliminates critical matrix interferences from lens 
samples which were not validated in the previous technique. It entails an isocratic RP- 
HPLC separation following pre-column derivatization of free thiols with ThioGlo-3, a 
maleimide-based fluorogenic probe (see Figure 2). Prior to derivatization, reduction with 
tris(2-carboxyethyl)phosphine (TCEP) and addition of an internal standard minimize 
effects of thiol oxidation during processing. The following validation studies demonstrate 
that this method can accurately and reliably quantify both MPG and its major metabolite 
MPA in ocular tissues and plasma at nanomolar concentrations.
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Figure 2. Derivatization of thiols with ThioGlo-3.
2. EXPERIMENTAL METHODS
2.1. CHEMICALS AND REAGENTS
MPG, MPA, N-acetylcysteine (NAC), TCEP, Tris-HCl, L-serine, and 
diethylenetriaminepentaacetic acid (DETAPAC) were all purchased from MilliporeSigma 
(St. Louis, MO, USA). Type I water was obtained using a Millipore Simplicity 185 water 
purification system. ThioGlo-3 was purchased from Covalent Associates, Inc. 
(Bellingham, WA, USA). All other reagents were purchased from Fisher Scientific 
(Pittsburgh, PA, USA). was adjusted to pH 7.4 with NaOH. All other reagents were 
purchased from Fisher Scientific. The injection vehicle for the animal study was a 
phosphate buffered saline (pH 7.4) consisting of 137 mM NaCl, 2.7 mM KCl, 8 mM 
Na2HPO4, and 1.5 mM KH2PO4. Serine borate buffer (SBB) consisting of 100 mM Tris- 
HCl, 5 mM L-serine, 10 mM H3BO3, and 1 mM DETAPAC was prepared in type 1 water 
and adjusted to pH 7.0 with NaOH.
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2.2. ANIMALS
All animal procedures were approved by the Missouri University of Science and 
Technology Animal Care and Use Committee. A litter of male Wistar rats weighing 12­
18 g were purchased from Charles River Laboratories (Wilmington, MA, USA). All 
animals were housed in a temperature-controlled room with a 12 h light-dark cycle. The 
rats were fed and watered ad libitum with Purina rat chow and municipal tap water. Six 
rats were fasted overnight prior to receiving an intraperitoneal injection of either MPG 
(250 mg/kg body weight) or vehicle alone. Forty minutes after receiving the injection, the 
animals were anesthetized, and blood was collected into heparin-coated Vacutainers (BD, 
Franklin Lakes, NJ, USA) via intracardiac puncture. The animals were euthanized and 
the whole eyes were immediately removed and carefully dissected in isotonic PBS to 
obtain the corneas, lenses, and retinas. Plasma was collected after centrifugation of whole 
blood samples at 2000 x g. All samples were stored in a freezer at -80°C until analysis.
2.3. SAMPLE PREPARATION
Corneas, lenses, and retinas were thawed and transferred to microcentrifuge tubes 
containing 500 pL of ice-cold SBB, spiked with 2.5 pM internal standard (NAC) and 75 
pM TCEP. The tissues were sheared in this buffer on ice using a Tissue-Tearor (BioSpec 
Products, Inc., Bartlesville, OK, USA). The samples were removed from ice and allowed 
to stand for 30 min for temperature equilibration and reduction of disulfide bonds. Matrix 
protein content was determined via the Coomassie dye-binding method described by 
Bradford. (Bradford, 1976) Briefly, Bradford dye reagent (Bio-Rad, Hercules, CA, USA) 
was diluted five-fold in SBB, and 2.5 pL of the working reagent was added to 50 pL of
tissue homogenate. The absorbance at 595 nm was recorded after 5 min. Aliquots from 
lens and retina homogenates were diluted 15-fold and 2-fold, respectively to keep protein 
levels within the working linear range for the Bradford assay. The homogenates were 
then centrifuged for 5 min at 11,000 x g. For derivatization, 100 pL of the supernatant 
solutions were transferred to tubes containing 25 pL of SBB and 375 pL of ThioGlo-3 
(33 pM in HPLC-grade acetonitrile). After 20 min, samples were acidified with 5 pL of 2 
N HCl, and then diluted with 250 pL of mobile phase component A.
Plasma samples were thawed, and 40-pL aliquots of plasma were diluted with 160 pL of 
SBB spiked with 2.5 pM internal standard and 75 pM TCEP, and allowed to stand for 30 
min. The diluted plasma samples were then centrifuged for 5 min. at 11,0000 x g. Then, 
125 pL of the supernatant solutions were transferred to tubes containing 375 pL of 33- 
pM ThioGlo-3. After 20 min, samples were acidified with 5 pL of 2 N HCl, and then 
diluted with 250 pL of mobile phase component A.
The samples were filtered into sampler vials using 0.2-pm nylon syringe filters (Fisher 
Scientific).
2.4. PREPARATION OF CALIBRATION STANDARDS
Calibration standards were prepared by spiking 25 pL of working solutions of 
MPG and MPA into 100 pL of pooled drug-free samples of the corresponding matrix, 
diluted in SBB spiked with internal standard and TCEP. The final concentrations of NAC 
and TCEP all of the calibration standards were 331 nM and 9.93 pM, respectively. 
Calibration standards were prepared at 9 levels over the range of 66.2 -  1656 nM for
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MPG and 33.1 -  828 nM for MPA.
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2.5. HPLC PARAMETERS
A Thermo Scientific Dionex UltiMate 3000 Series HPLC system equipped with a 
Dionex LPG-3400-SD pump, a Dionex ACC-3000 autosampler, and a Dionex FLD-3100 
fluorescence detector was used for the duration of this study. The analytes were separated 
in a Kinetex Ci8 column (75 mm x 4.6 mm i.d.) with 2.6-pm superficially porous 
particles (Phenomenex, Torrance, CA, USA). The column oven was set to 30°C. The 
mobile phase was prepared by on-line mixing of two components (isocratic 1:1 blend). 
Component A was prepared by diluting 1.00 mL of 85% H3PO4 (HPLC-grade) to 900 mL 
with Type 1 water, adjusting the pH to 2.46 by dropwise addition of NaOH, and diluting 
to a final volume of 1 L. Component B was prepared by mixing 200 mL of component A 
with 800 mL of HPLC-grade acetonitrile. Both components were filtered using 0.22-pm 
nylon membrane filters (Foxx Life Sciences, Salem, NH, USA) and degassed prior to 
use. The mobile phase was pumped at a flow rate of 3.0 mL/min. Separation was 
completed within 3.5 min. The xenon lamp was operated in “Standard” mode, and the 
detector sensitivity settings were adjusted according to the timetable shown in Table 1.









0.000 365 445 1
0.760 365 445 5
1.900 365 445 8
*Each sensitivity level represents an 8-fold increase in detector response.
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2.6. METHOD VALIDATION
Validation of the method described here was performed in accordance with the 
USP and ICH guidelines. Specific definitions and approaches to the parameters validated 
are given below:
2.6.1. Selectivity. Selectivity was determined for each matrix. Spiked and 
unspiked samples of each matrix taken from six different animals were individually 
processed and analyzed as described above. Chromatograms from spiked and unspiked 
samples were compared to determine whether there were any endogenous sources of 
interference with the NAC, MPG, and MPA peaks.
2.6.2. Linearity and LLOQ. Linearity was assessed from calibration standards 
prepared at nine concentration levels for each matrix. Standards for each calibration point 
were prepared in triplicate. Concentration ranges were chosen to reflect those expected 
after administration of MPG. For each curve, the concentration of calibration standards 
was plotted against the analyte’s peak area relative to that of the internal standard. 
Calibration curves were calculated by unweighted linear least-squares regression. The 
LLOQ in each matrix was accepted as the lowest standard concentration point on the 
curve that exhibited less than 20% RSD from the mean and less than 20% relative 
deviation from the target concentration.
2.6.3. Sample Stability. The stability of the processed samples was evaluated for 
typical storage conditions, including storage on the autosampler tray at 30°C for up to 12 
hours, at 4°C for up to one week, and after three freeze-thaw cycles from -80°C. Stability 
of MPG and MPA in sample matrix was also evaluated over 3 hours at room temperature 
and 48 hours at -80°C. The determination of sample stability was made using triplicate
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samples matrices spiked with low (166 nM MPG, 83 nM MPA) and high (662 nM MPG, 
331 nM MPA) levels of MPG and MPA. Stability was reported as the ratio of the 
detector response obtained from samples subjected to the indicated storage conditions to 
that of replicate samples injected immediately.
2.6.4. Precision, Accuracy, and Recovery. Precision, accuracy, and relative 
recovery were evaluated in each matrix spiked with high (662 nM MPG, 331 nM MPA), 
medium (331 nM MPG, 166 nM MPA), and low (166 nM MPG, 83 nM MPA) levels of 
MPG and MPA. Five replicate samples were analyzed for each level. Intra-assay 
precision is reported as the coefficient of variation (%CV) of five replicate samples 
analyzed in the same analytical run. Inter-assay precision is reported as the %CV for 15 
replicate spiked samples processed over three different days by two different analysts 
with freshly prepared reagents. For determination of relative recovery, spiking solutions 
of MPG and MPA were added to samples prior to sample processing. The recovery is 
reported as the ratio of the detector response from samples spiked before processing to 
the response obtained from analogous samples spiked just prior to derivatization.
3. RESULTS AND DISCUSSION
MPG is an important pharmaceutical for the management of diseases such as 
cystinuria and rheumatoid arthritis, and its antioxidant properties may find use in a 
number of oxidative stress-related conditions, including cataracts and other age-related 
eye diseases. For this purpose, it is necessary to understand the distribution of MPG and 
its major metabolite MPA in ocular tissues as well as its absorption into the bloodstream.
Moreover, preliminary experiments conducted in our lab suggest that MPA is also a 
potent free radical scavenger, and as such, an important contributor to the therapeutic 
effects of MPG. In recent years, drug delivery vehicles have emerged as a promising 
strategy for increasing drug penetration and residence in the eye. However, in order to 
evaluate their ability to increase MPG concentrations in the eye, a sensitive and reliable 
method for monitoring MPG levels in ocular tissues needed to be developed and 
validated.
3.1. CHROMATOGRAPHY
The method described herein is based on one previously developed by our group 
(Penugonda et al., 2004). However, the newer method offers several key advantages over 
the original and overcomes some key limitations. Although the method described by 
Penugonda et al. was suitable for determination of MPG in a number of other biological 
matrices, it was not suitable for our more recent studies investigating ocular drug uptake. 
This was mainly due to the presence of endogenous compounds that would co-elute with 
MPG. As a result, it was necessary to modify and re-validate the method for this 
application. In order to achieve the separation required to eliminate the interference, a 
column with higher efficiency was selected, and a new mobile phase composition was 
optimized based on the results of typical scouting gradient experiments.
Some representative chromatograms are shown in Figure 3. ThioGlo-3 alone 
produced a detectable peak at 3.4 min. Addition of TCEP gave rise to a high intensity 
peak that is retained for 0.5 min, and a lower intensity peak with a retention time of 1.7 
min. The internal standard, NAC, is retained for 1.1 min. Derivatization of MPG and
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MPA gave rise to two peaks each. Derivatized adducts of MPG were eluted after 1.3 min 
and 1.4 min, and adducts of MPA were eluted after 2.3 min and 2.5 min.
Figure 3. Overlay of representative chromatograms from samples containing A, ThioGlo- 
3 in sample diluent; B, ThioGlo-3 + TCEP; C, ThioGlo-3 + TCEP + NAC; D, ThioGlo-3 
+ TCEP + NAC + MPA; E, ThioGlo-3 + TCEP + NAC + MPG + MPA. The peaks are 
associated with the indicated analytes 1, NAC; 2,3, MPG; 4,5, MPA.
MPG and MPA are both chiral thiols, each containing a single stereocenter. When 
these chiral thiols react with a maleimide probe such as ThioGlo-3, a second stereocenter 
is formed as shown in Figure 4. Thus, four stereoisomers are possible. (Kullman et al., 
2000) We hypothesize, therefore, that the two diastereomeric pairs were separated due to 
the increased chromatographic efficiency of this method. Although multiple products 
were formed following derivatization of MPG and MPA, quantitation was not 
significantly hindered. The formation of fluorescent adducts following derivatization with
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ThioGlo-3 was quantitative and reproducible, and the results were consistent when using 
MPG sourced from different manufacturing lots. Furthermore, baseline resolution was 
achieved for all relevant peaks across the working concentration range (resolution > 2.07, 
USP). For determination of MPG and MPA, the greatest precision and accuracy were 
achieved by integrating the peaks eluting at 1.4 min for MPG and 2.3 min for MPA.
Figure 4. Derivatization of thiols containing a stereocenter gives rise to products with two
stereocenters.
As an isocratic separation that is completed within 3.5 min, this method requires 
only 12 mL of mobile phase per run, only 40% of which is organic solvent. Furthermore, 
this method offers greater sensitivity than those utilizing UV detection and poses less of 
an economic barrier to researchers compared to methods utilizing LC-MS, which can be 
prohibitively expensive to acquire and maintain. Thus, the method described here is 




Figure 5 shows representative chromatograms obtained from the analysis of 
spiked and unspiked plasma, cornea, lens, and retina extracts. The matrices investigated 
did not contain any detectable, endogenous compounds that would co-elute and interfere 
with the analytes of interest. Most of the endogenous aminothiols such as GSH, cysteine, 
homocysteine, and CysGly elute within the first 60 seconds. The derivatization technique 
coupled with the separation and detection method produces interference-free 
chromatograms, making the technique selective for NAC, MPG and MPA.
3.3. LINEARITY AND LLOQ
The calibration curves (sample shown Figure 6) were created by plotting the 
concentration of calibration standards vs. the analyte’s peak area relative to that of the 
internal standard. The regression data from each calibration curve is summarized in Table
2. The linear ranges achieved for MPG and MPA in each of the matrices were suitable for 
determinations in real samples. The smallest level on the calibration curve that was 
accurate within 20% of the target concentration and with less than 20%RSD was 
accepted as the LLOQ for MPG and MPA in each matrix. The LLOQs achieved ranged 
from 66 -  99 nM for MPG and were < 33 nM for MPA per 10 pL injection.Given the 
drug availability challenges associated with the eye and the relatively small size of the 
ocular tissues, low LLOQs are necessary for studies investigating ocular drug uptake and 
retention. This is difficult to achieve with other methods available such as those utilizing 
UV detection; however, the use of fluorescence detection offers much higher 
sensitivity.(Kusmierek, Chwatko, Glowacki, & Bald, 2009) One disadvantage resulting
from the separation of stereoisomers of MPG and MPA is that the LOD and LLOQ are 
increased; however, the limits were still suitable for our applications.
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Figure 5. Representative chromatograms from processed tissue samples. Each plot 
depicts an overlay of the spiked matrix (B) on top of the unspiked matrix (A). Spiked 
matrices contained 500 pmol of NAC, 500 pmol of MPG, and 250 pmol of MPA during 
derivatization. Unspiked matrices contained 500 pmol of NAC. Peak labels: 1, NAC ; 
2,3, peaks arising from MPG derivatization; 4,5, peaks arising from MPA derivatization.
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Figure 6. Calibration curves for MPG (left) and MPA (right) diluted in SBB. The solid 
black dots represent the mean response from three replicate injections.
Table 2. Summary of linear regression
Matrix Analyte Regression equation R2 Linear range, nM LLOQ, nMa
SBB MPG y = 0.1904x - 8.319 0.9991 66 - 1656 99.34
MPA y = 0.4078x - 1.616 0.9997 33 - 828 33.11
Plasma MPG y = 0.0566x - 2.9861 0.9979 66 - 828 66.23
MPA y = 0.778x - 6.1789 0.9998 33 - 828 33.11
Cornea MPG y = 0.1958x - 12.1028 0.9987 66 - 1656 66.23
MPA y = 0.442x - 3.085 0.9998 33 - 828 33.11
Lens MPG y = 0.2363x - 11.5415 0.9997 66 - 1656 66.23
MPA y = 0.738x - 6.9977 0.9997 33 - 828 33.11
Retina MPG y = 0.2171x - 15.8672 0.9973 66 - 1656 99.34
MPA y = 0.4418x - 2.9531 0.9999 33 - 828 33.11
aLLOQ is given for an injection volume of 10 pL.
3.4. SAMPLE STABILITY
Due to the oxidizable nature of the aminothiol analytes and the nature of the 
sample, it is important to ensure that the sample will be stable enough under typical 
storage and exposure conditions to be reliably analyzed. Since aminothiols are prone to 
oxidation, it is recommended to derivatize or otherwise stabilize the samples as soon as 
possible. Spiked matrix samples left at room temperature for 3 hours or frozen at -80°C
for 48 hours before reduction and derivatization provided results within 2% deviation 
from samples injected immediately. Processed samples were evaluated at 30°C for up to 
12 hours to ensure stability while queued on the autosampler rack. Additionally, stability 
was evaluated after storage for 1 week at 4°C, as well as after three freeze-thaw cycles. 
The results of these experiments are summarized in Table 3. After the samples have been 
processed, they are stable beyond typical handling conditions. All samples were stable at 
30°C for at least 12 hours. Acceptable stability was also achieved after storage for up to 
one week at 4°C, and after three freeze-thaw cycles of samples stored at -80°C.
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Table 3. Stability of derivatized samples
30°C 30°C 4°C Three freeze-thaw
Spike 6 hours 12 hours 1 week cycles
Levela --------------------------------------------------------------------------------------------------------------
MPG MPA MPG MPA MPG MPA MPG MPA
SB
B L 101.9% 97.2% 99.6% 96.9% 96.2% 103.7% 95.9% 98.3%




a L 96.3% 103.9% 97.6% 99.2% 97.6% 112.2% 97.6% 105.7%




a L 99.5% 97.8% 101.7% 93.8% 100.6% 101.5% 99.2% 98.3%
H 100.0% 100.5% 100.8% 99.8% 99.0% 99.6% 98.9% 96.3%
Le
ns
L 98.0% 98.0% 98.3% 95.7% 97.8% 104.2% 97.7% 103.5%




a L 100.0% 100.9% 99.1% 99.8% 97.3% 110.2% 98.1% 111.9%
H 101.0% 100.3% 101.8% 97.9% 97.0% 100.0% 97.7% 100.7%
a Spike levels: L, 166 nM MPG, 83 nM MPA; H, 662 nM MPG, 331 nM MPA
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The convenient one-step reduction and addition of internal standard provides for 
greater sample stability with respect to oxidation, evaporation, and processing. 
Furthermore, the reduction step allows for determination of total MPG and MPA, by 
freeing up protein bound MPG and MPA or other mixed disulfides. This is particularly 
important, as their hypothesized mechanisms of action involve thiol-disulfide exchange, 
indicating that a significant portion of MPG and MPA may be oxidized at their sites of 
action.
3.5. PRECISION, ACCURACY, AND RECOVERY
Precision, accuracy, and relative recovery were determined according to the USP 
and ICH guidelines. The results are summarized in Table 4.
Table 4. Precision, accuracy, and recovery






(%CV) (%RE) (%, mean ± S.D.)
MPG MPA MPG MPA MPG MPA MPG MPA
SBB L 0.51 1.11 3.00 2.16 10.14 -3.85 n.a. n.a.
M 0.34 1.38 2.28 2.23 1.99 -3.72 n.a. n.a.
H 0.16 0.52 0.56 1.07 0.74 -1.13 n.a. n.a.
Plasma L 4.15 3.03 6.99 3.65 -10.25 5.16 111.3 ± 2.39 97.4 ± 2.36
M 5.40 0.76 5.89 2.83 -8.74 1.50 104.5 ± 4.43 98.8 ± 1.56
H 2.59 1.29 2.72 2.32 -13.25 -1.19 111.4 ± 8.07 102.4 ± 1.13
Cornea L 0.65 0.98 3.40 1.32 -3.06 -2.49 98.3 ± 0.14 100.1 ± 1.71
M 0.29 0.55 2.09 1.68 5.42 -4.14 96.4 ± 0.59 102.3 ± 0.61
H 0.10 0.30 0.78 0.67 5.66 -4.26 99.9 ± 1.60 102.0 ± 0.38
Lens L 2.04 2.17 4.50 2.67 -4.63 5.45 110.9 ± 2.96 99.1 ± 4.08
M 0.60 1.01 3.61 1.48 -7.31 0.98 111.7 ± 0.53 102.5 ± 1.50
H 0.60 0.69 1.23 0.75 -5.02 1.77 111.3 ± 0.72 102.5 ± 1.97
Retina L 0.84 1.95 1.01 2.28 4.11 -3.34 99.4 ± 0.45 104.5 ± 0.34
M 0.21 0.67 1.96 2.25 0.43 -2.76 99.5 ± 1.43 103.3 ± 0.50
H 0.26 0.30 1.16 1.04 1.26 -4.79 101.4 ± 1.92 105.0 ± 0.36
a Spike levels: L, 166 nM MPG, 83 nM MPA; M, 331 nM MPG, 166 nM MPA; H, 662 nM
MPG, 331 nM MPA
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Intra-day and inter-day precision for all samples were below 5.5% and 7.0% RSD, 
respectively. Determinations in plasma samples were accurate within 13.3% of the spiked 
concentration while those from ocular tissues were accurate within 7.4% of the spiked 
concentration. The relative recovery was consistent across low, medium, and high spikes 
of MPG and MPA within matrices. All values were within the acceptability criteria.
3.6. DETERMINATION OF MPG AND MPA IN PLASMA AND OCULAR 
TISSUES
The method validated as described above was successfully applied for the 
simultaneous determination of MPG and MPA in Wistar rat plasma and ocular tissues 
following injection of MPG. Wistar rats were administered PBS or MPG (250 mg/kg 
body weight) by intraperitoneal injection. This dose is relatively high compared to those 
used in human patients, which was necessary in order to observe even low levels of MPG 
in ocular tissues. None of the animals were given MPA. Samples were processed as 
described in the methods section. The results are summarized in Table 5.
Table 5. MPG and MPA concentration in Wistar rat tissues 40 min after intraperitoneal
administration of MPG
Sample [MPG] [MPA]
Mean ± Standard Deviation (N = 3)
Plasma 88.30 ± 9.13 pM 9.13 ± 3.50 pM
Cornea 11.93 ± 1.36 nmol/mg protein 1.36 ± 1.06 nmol/mg protein
Lens 0.41 ± 0.12 nmol/mg protein 0.12 ± 0.07 nmol/mg protein
Retina 2.43 ± 1.42 nmol/mg protein Not detected
No MPG or MPA was detected in samples collected from animals injected with 
PBS. Both MPG and MPA were present in plasma, cornea, and lens samples from the 
animals that were injected with MPG. Since MPA was not detected in the animals 
injected with PBS, this indicates that MPG was metabolized to MPA following injection. 
The retina did not contain detectable levels of MPA, but low levels of MPG were present.
Although a similar method for analysis of MPG in biological tissues was 
developed in our lab and described by Penugonda (Penugonda et al., 2004), endogenous 
interferences prevented determination of MPG in lens tissue, and thus it was unsuitable 
for evaluating ocular uptake of MPG. Furthermore, the method described here offers a 
number of significant improvements over the previous method: First of all, this method 
simultaneously measures concentrations of MPA as well as MPG. In addition, TCEP 
reduction allows for determination of total MPG, comprising its oxidized and reduced 
forms. The current method’s use of an internal standard greatly improves accuracy and 
robustness. Finally, the new method is twice as fast. Therefore, this method is more 




A reliable HPLC-FLD method was developed for simultaneous determination of 
MPG and its major metabolite, MPA. Because this drug exhibits potential as an 
antioxidant treatment for cataracts, the method was validated in ocular tissue matrices
and plasma for the purpose of monitoring the uptake and distribution of the drug
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throughout treatment. The method was successfully applied to the analysis of plasma and 
ocular tissues of animals injected with MPG, wherein both analytes MPG and MPA were 
detected in animals treated with the drug. While other techniques for the analysis of MPG 
exist, the method described here accomplishes it isocratically in under 4 minutes with 
widely available instrumentation. Moreover, the reduction step and internal standard 
confer stability with respect to oxidation during processing and other variations in sample 
handling, making this method ideal for routine analysis of MPG and MPA in both basic 
research and clinical settings.
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ABSTRACT
Tiopronin is an FDA-approved thiol drug currently used to treat cystinuria and 
rheumatoid arthritis. However, due to its antioxidant properties, it may be beneficial in a 
variety of other conditions. One primary obstacle to its wider application is its limited 
bioavailability, which necessitates administration of high systemic doses to achieve 
localized therapeutic effects. Incorporation of a drug delivery vehicle can solve this 
dilemma by providing a means of controlled, targeted release. Functionalized 
nanodiamond is a promising theranostic platform that has demonstrated great potential 
for biomedical applications, including drug delivery. Design of nanodiamond theranostic 
platforms requires comprehensive understanding of drug-platform interactions, and the 
necessary physical chemical investigations have only been realized for a limited number 
of compounds. Towards the long-term goal of developing a nanodiamond-tiopronin 
treatment paradigm, this study aims to shed light on the effects of nanodiamond surface
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chemistry on adsorption and release of tiopronin. Specifically, adsorption isotherms were 
measured and fit to Langmuir and Freundlich models for carboxylated, hydroxylated, and 
aminated nanodiamonds, and release was monitored in solutions at pH 4.0, 5.8, 7.3, and
8.1. Our results indicate that aminated nanodiamonds exhibit the highest loading capacity 
while hydroxylated nanodiamonds are the most effective for sustained release. Therefore, 
a high degree of flexibility may be afforded by the use of nanodiamonds with different 
surface chemistries optimized for specific applications.
Keywords: Nanodiamond; Functionalization; Adsorption; Desorption; Drug delivery
1. INTRODUCTION
Tiopronin is a low-molecular-weight thiol drug used for the treatment of 
rheumatoid arthritis and cystinuria. It has also demonstrated potential benefits in a variety 
of other conditions, including heavy metal1 and radiation poisoning,2 and cataract.3 A 
primary mechanism of its action in these conditions is the direct scavenging of free 
radicals and maintenance of healthy levels of glutathione (GSH), a vital antioxidant and 
the body's most abundant non-protein thiol.4-5However, the effectiveness of tiopronin is 
limited by its bioavailability. Tiopronin is weakly acidic and becomes deprotonated at 
physiological pH. The negatively charged conjugate base (Figure 1) cannot easily 
penetrate the low polarity lipid bilayer of cell membranes. Furthermore, when 
administered topically, insufficient residence time on physiological barriers such as the 
skin or cornea can severely curtail its uptake and deeper penetration into tissues.6 These 
effects necessitate the administration of higher dosages, increasing the risk and severity
of adverse side effects. It is therefore desirable to provide a means by which small 
hydrophilic molecules such as tiopronin can be transported and released in a controlled 
manner at their desired site of action. Towards this end, drug delivery vehicles offer a 
promising alternative to the large systemic doses of neat drug and excipient used 
currently.7 For example, it has been shown that poloxamer hydrogels significantly 
enhanced uptake and effectiveness of tiopronin in a rat model of age-related nuclear
ocataracts.8
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In addition to providing controlled transport and release of a well-defined and 
therapeutically consequential payload, drug delivery vehicles must be highly 
biocompatible and stable under formulation conditions (which may include autoclaving 
or irradiation). Sustained release is also desirable, given that the conditions mentioned 
above may be long-term or chronic illnesses. In these respects, hydrogels present many 
challenges with regard to chemical stability, longevity, and especially sustained and 
controlled release.9 Nanodiamonds (NDs), however, are not subject to these limitations. 
Detonation nanodiamonds, which are inexpensive and commercially available, are 
nontoxic and are considered the most biocompatible of all carbon nanoparticles.10 Each 
ND particle possesses a core of sp3 hybridized carbon that is chemically inert and similar 
to bulk diamond, while the surface comprises fully exposed, covalently attached
functional groups that can be tailored for optimal interaction with the drug payload and 
environment.10-11 Modification of surface chemistry affords a high degree of control, 
specificity, and flexibility with respect to drug-ND interaction.12-14 Here we investigate 
the potential of ND as a promising candidate platform for delivery and sustained release 
of tiopronin.
A critical step in assessing the suitability of a drug delivery platform is to 
determine its capacity to carry and release the compound of interest. 
Adsorption/desorption is the simplest and therefore preferred mechanism of loading and 
release. It requires no chemical modification of the drug, which reduces risks of 
interfering with its biological activity.13 The rich surface chemistry of ND allows for a 
high degree of control over drug-ND interactions, which is exerted through the creation 
of functional groups such as -COOH, -OH, or -NH2 on the ND surface. Controlling ND 
surface chemistry can significantly affect loading capacity, strength of binding, and 
release of the desired drug.14 Because tiopronin is negatively charged at physiological 
pH, the electrostatic interaction between adsorbent and adsorbate can be tailored to 
optimize the drug delivery platform.
Although understanding adsorption and release is essential for development of 
ND-drug complexes capable of delivering well-defined dosages, these phenomena have 
been largely unexplored for ND as a carrier of tiopronin or other similar thiol drugs. By 
understanding the effects of surface functionalization on ^-potential, adsorption 
monolayer capacity, and cumulative drug release, we can determine the optimal surface 
chemistry for ND-mediated delivery of tiopronin for a variety of conditions. Consistent 
and reliable delivery of tiopronin and related compounds can pave the way for more
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targeted treatment regimens that produce the same therapeutic effects with significantly 
lower incidence of side effects.
2. EXPERIMENTAL METHODS
2.1. MATERIALS AND REAGENTS
UD90 ND powder was donated by NanoBlox, Inc. Tiopronin, tris(2- 
carboxyethyl)phosphine (TCEP), N-acetylcysteine (NAC), and K2HPO4 were purchased 
from MilliporeSigma (St. Louis, MO, USA). ThioGlo-3 was purchased from Covalent 
Associates Inc. (Bellingham, WA, USA). All other reagents were purchased from Fisher 
Scientific (Pittsburgh, PA, USA). Type 1 water was prepared in-house using a Millipore 
Simplicity 185 purification system (MilliporeSigma). Citrate-phosphate buffers were 
prepared to the desired pH by mixing 0.1 M citric acid with 0.2 M Na2HPO4 in varied 
ratios as shown in Table S1. The pH 8.1 buffer was prepared by dissolving 1.628 g of 
K2HPO4 and 0.089 g of KH2PO4 in type 1 water and then diluting to a final volume of 
100 mL in a volumetric flask.
2.2. PURIFICATION AND SURFACE MODIFICATION OF ND
To remove non-diamond carbon, 2.0 g of as-received ND were placed into a 50­
mL porcelain crucible and heated in air at 425°C for 2 hours in a Thermolyne 2L D1 
Benchtop Muffle Furnace (Thermo Scientific).15 Then, the NDs were refluxed overnight 
in 50 mL (1:1) volume of 35 wt. % aqueous HCl : 70 wt. % aqueous HNO3 to remove 
traces of metals and metal oxides and to hydrolyze surface anhydrides. The mixture was 
then allowed to cool to ambient temperature. Excess acids were removed by decanting
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followed by several cycles of rinsing and centrifuging with deionized water until the pH 
was neutral. Then, the mixture was dried in a desiccator with drierite under vacuum at 
ambient temperature for about two days, yielding a purified carboxylated ND (ND- 
COOH). This ND-COOH was used as a starting material for the synthesis of all other 
functionalized NDs in this work.
Aminated ND (ND-NH2) was produced in two stages: 1) conversion of ND- 
COOH to acyl chloride ND (ND-COCl), 2) reaction of ND-COCl with ethylenediamine 
(EDA).16 In the first stage, a mixture of 1.0 g of ND-COOH in a 100 mL round-bottom 
flask with a Teflon-coated magnetic stirrer bar, 50 mL thionyl chloride (SOCh), and 0.5 
mL of anhydrous dimethylformamide (DMF) as a catalyst was sonicated in an ultrasonic 
bath to break all visible ND agglomerates. The flask was then connected to a condenser 
closed with a drierite-filled drying tube and heated overnight under reflux at ~70 °C to 
yield ND-COCl. The flask was then cooled to ambient temperature, and excess SOCl2 
was removed by vacuum distillation at < 50 °C to suppress thermal decomposition of 
SOCl2. The residual solid was rinsed six times with 50 mL anhydrous THF, and excess 
THF was decanted. The solid was then dried overnight in a desiccator containing drierite 
under vacuum at ambient temperature. In the second stage, 1.0 g of dry ND-COCl was 
mixed with 50 mL anhydrous ethylenediamine in a 100 mL round-bottom flask 
containing a Teflon coated magnetic stirrer bar. The mixture was sonicated in an 
ultrasonic bath until all visible agglomerates of nanodiamond disappeared. The flask was 
then connected to a condenser closed with a drierite drying tube and heated overnight at 
~60 °C under reflux. After cooling to ambient temperature, ND-NH2 powder was 
precipitated, and excess EDA was gently removed using a pipette. The resulting ND-NH2
powder was rinsed six times with 50 mL fresh anhydrous THF to remove any traces of 
adsorbed EDA. A few drops of THF from the last wash were mixed with ~10 mL of 
deionized water, and the pH of the solution was measured to test for complete removal of 
EDA, as indicated by neutral pH. The resulting ND-NH2 was dried on a watch glass at 
room temperature in ambient air. Aminated ND was characterized as reported before.16
Hydroxylated ND (ND-OH) was synthesized as described previously.17 1.0 g ND- 
COOH was purged several times with argon gas in a 250-mL Schlenk flask containing a 
Teflon-coated magnetic stirrer bar. Anhydrous tetrahydrofuran (THF) was degassed by 
purging with argon gas for one hour. 5 mL of degassed THF was added to the Schlenk 
flask containing ND-COOH, and the mixture was sonicated to break all visible 
agglomerates. Then, 10 mL of a 2.0 M solution of lithium aluminum hydride (LiAlH4) in 
THF was added. The mixture was stirred overnight at ambient temperature under argon. 
The excess of (LiAlH4) was quenched by dropwise addition of 1 M HCl. Then, 1 M KOH 
was added until neutral pH. The product was rinsed and centrifuged several times with 
water and finally with acetone. The resulting ND-OH was dried overnight at 90 °C.
2.3. CHARACTERIZATION OF FUNCTIONALIZED ND
Transmission Electron Microscopy (TEM) was carried out using an FEI Tecnai 
G2 F20 S-TWIN transmission electron microscope equipped with field-emission gun, 
operated at 200 kV. TEM samples were prepared by drop-casting aqueous ND 
suspensions onto carbon-coated copper grids followed by drying in the ambient 
atmosphere. Additional structural information was obtained by small-area electron 
diffraction (SAED), performed using the same instrument. X-ray diffraction (XRD)
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analysis of as-received ND was conducted using a PANalytical X’Pert multipurpose 
diffractometer (Malvern Instruments, Ltd., Malvern, UK), powered by a Philips 
PW3064/60 X-ray generator with a Cu Ka (X = 1.540598 A) radiation source. Fourier 
Transform Infrared (FTIR) spectra were recorded using a Thermo Nicolet NEXUS 470 
FT-IR Spectrometer, in a range 400-4000 cm-1 with 1 cm-1 resolution. Pellets were 
prepared by pressing a mixture of 2 mg ND and 200 mg KBr under a load of 10-15 tons. 
A Zetasizer Nano ZSP and an MPT-2 multi-purpose titrator (Malvern Instruments, Ltd.) 
were used to determine Z-potential and size of the ND agglomerates as a function of pH 
(Z-potential titration) at 23 °C. For all NDs, 10 mL of 0.01 wt. % ND colloidal solution 
was used to measure Z-potential and average particle size with 0.5 pH steps over a pH 
range 2.0 -  9.0 with three measurements at each pH. To minimize initial aggregation, for 
negatively charged ND-COOH the starting pH was 9.0, and for positively charged ND- 
NH2 and ND-OH the starting pH was 2.0. The titrator was thoroughly cleaned and primed 
after every sample measurement to avoid contamination and remove air bubbles, and the 
pH probe was properly calibrated to ensure accurate results.
2.4. ADSORPTION STUDY
ND stock suspensions were prepared in pre-weighed, reinforced RINO 
microcentrifuge tubes (Next Advance, NY, USA) by dispersing functionalized NDs in 
type 1 water at a nominal concentration of 1.4 wt. %. The actual concentration of each 
stock solution was determined by weighing the NDs and the ND-water suspension. The 
NDs were dispersed by bombarding the outsides of the RINO tubes in a Bullet Blender 
Storm (Next Advance) at max speed for 10 min. The tubes were then sonicated in an
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ultrasonic bath for 20 min. The tubes containing ND stocks left to equilibrate to room 
temperature on a rotator. The contents of the tubes were vigorously vortexed immediately 
before any liquid transfer procedures. The density of each stock ND suspension was 
determined by weighing aliquots measured out with a volumetric pipette. The density 
was used to convert the concentration from mg ND/g solution to units of mg/mL. 
Appropriate dilutions were made to aliquots of ND stocks with type 1 water to yield a 
working concentration of 2.00 mg/mL. An 804 ppm stock solution of tiopronin was 
prepared by dissolving 80.4 mg of tiopronin in type 1 water in a 100-mL volumetric 
flask. All working solutions were prepared by dilutions of this stock solution. In 2-mL 
microcentrifuge tubes, 500 pL of 2.00 mg/mL ND working solutions were mixed with 
500 pL of the appropriate working tiopronin solution to produce samples containing 1 
mg/mL functionalized ND and 0-200 ppm tiopronin. The samples were thoroughly mixed 
by vortexing and placed on a rotator for 24 hours. After this time, the samples were 
placed in a centrifuge and subjected to 12,000 x g for 12 min. The supernatants were 
collected and centrifuged again at 12,000 x g for 12 min to remove any remaining NDs. 
Free tiopronin was determined in the supernatant using a sensitive HPLC technique 
described previously.18 Briefly, the supernatant was diluted as necessary, and 25 pL of 
supernatant was added to 100 pL of reducing buffer (75 pM TCEP and 2.5 pM NAC in 
pH 7.0 citrate-phosphate buffer). The sample was then derivatized by the addition of 375 
pL of 33 pM ThioGlo-3. The derivatized sample was acidified by the addition of 5 pL of 
2 M HCl and diluted with 250 pL of 15 mM H3PO4. Finally, the sample was filtered and 





The release study methodology was adopted from a previous investigation.13 
NDs were loaded with tiopronin by mixing 6.1 mL of 2.00 mg/mL ND in 15-mL 
centrifuge tubes with 6.1 mL of 80, 200, or 400 ppm tiopronin for ND-COOH, ND-OH, 
and ND-NH2, respectively. These concentrations were selected based on the maximum 
monolayer adsorption capacity of each ND type, as determined in the adsorption study. 
The tubes were placed on a rotator for 24 hours to equilibrate. After this time, 12 mL of 
each loaded ND sample was divided into 12 pre-weighed 2-mL microcentrifuge tubes. 
The loaded NDs were centrifuged as described previously, and the supernatants were 
carefully removed with a pipette. The supernatants were analyzed in the same manner as 
the adsorption samples to determine the amount of tiopronin adsorbed in each sample. To 
wash away unbound tiopronin, the loaded NDs were rinsed with 1000 pL of type 1 water. 
The samples were centrifuged to precipitate the NDs, and the water was carefully 
removed with a pipette. This step was repeated once more. After washing, the loaded ND 
precipitates were dried under vacuum in a Vacufuge Concentrator 5301 (Eppendorf, 
Hauppauge, NY, USA) heated to 60°C. The NDs were left to dry for at least 3 hours, 
until they had a dry, cracked appearance. The mass of ND remaining in each tube was 
determined by subtracting the weight of the empty tube from that of the tube with dried 
NDs. The weight of adsorbed tiopronin molecules was negligible. To investigate the 
relationship between pH and tiopronin release, the loaded NDs were divided into four 
groups per ND type (pH 4.0, 5.8, 7.3, and 8.1) with 3 replicates per group. The loaded 
NDs were resuspended by vortexing in a buffer solution with a pH corresponding to the 
group. The volume of buffer added was based on the mass of ND remaining in each tube
after rinsing and drying such that the ND concentration would be 1 mg/mL. The tubes 
were placed on a rotator during the desorption study. Every 24 hours, the tubes were 
centrifuged to precipitate the NDs as described previously. Sample volumes equal to 15% 
of the total buffer volume were collected from the supernatant solution for tiopronin 
analysis. This volume was replaced with an equal volume of fresh buffer, and the NDs 
were resuspended by vortexing. The tubes were then returned to the rotator. The samples 
were analyzed for tiopronin in the manner described in previous sections, however, 
separate calibration standards were prepared for each of the pH 4.0, 5.8, 7.3, and 8.1 
buffers to account for matrix effects during analysis (Figures S1-4). Determinations of 
statistical significance were made using two-way ANOVA followed by a Bonferroni post 
hoc test using GraphPad Prism 5.
3. RESULTS AND DISCUSSION
3.1. CHARACTERIZATION OF FUNCTIONALIZED ND
Representative TEM micrographs of ND-COOH are shown in Figure 2. Figure 
2A shows a low-resolution image of an ND-COOH sample, which reveals typical 
morphology of detonation nanodiamonds dried on TEM grid. The sample appears 
uniform, and although separate single nanodiamond particles were found in the sample, 
larger clusters were primarily observed. The high resolution TEM image of ND-COOH 
in Figure 2B shows 0.206 nm (111) d-spacing of crystalline diamond. The selected-area 
electron diffraction (SAED), shown in Figure 2C, confirms the diamond crystalline 
structure of the ND-COOH particles, with strong SAED rings corresponding to (111),
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(220), and (311) planes of ND with d-spacing of 0.206 nm, 0.127 nm, and 0.109 nm, 
respectively. The measured d-spacing values match well with the structure of cubic 
diamond. 19-20 XRD of the as-received ND (Figure 3A) shows three prominent peaks 
consistent with diffraction of diamond at 29 = 43.9°, 75.2° and 91.3° indexed as (111), 
(220) and (311) planes in cubic diamond.
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Figure 2. A. Low resolution and B. High resolution TEM micrographs of ND-COOH 
showing 0.206 nm d-spacing. C. Selected area electron diffraction pattern of ND-COOH 
sample consistent with small ND primary particle size and diffraction rings 
corresponding to the (111), (220), and (311) planes of diamond.
Surface chemistry of ND, ND-COOH, ND-OH and ND-NH2 was characterized 
by FTIR spectroscopy (Figure 3B-C). Figure 3C confirms covalent bonding of amino 
groups to ND surface in ND-NH2. The peaks at 3418 cm-1 present in all ND spectra 
correspond to O-H stretching vibrations and could be assigned to O-H or adsorbed 
water.21 The C-H stretch bands at ~2870 and ~2923 cm-1 originate from hydrogen atoms 
attached to ND surface, as well as from CH2 groups of EDA in ND-NH2. The bands at
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1637 cm-1 and ~3418 cm-1 in ND-NH2 arise from the bending and stretching modes of N- 
H as well as remaining O-H bonds.21-22 ND-NH2 amide peaks correspond to blue-shifted 
Amide I (1667 cm-1) and Amide II (1520 cm-1), as well as Amide III (~1320 cm-1)
(Figure 3C).22 A small C=O band at 1776 cm-1 in ND-NH2, suggests the presence of 
carbonyl species (carboxylic acids, ketones, esters, etc.) in the ND-NH2.16
O-H (stretch)
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Figure 3. A. XRD pattern of as-received ND. B. FTIR spectra of as-received ND, ND- 
COOH, ND-OH, and ND-NH2. C. FTIR spectra of ND-COOH and ND-NH2 in the range 
of wavelength corresponding to Amide bands. Dashed lines indicate absorbance 
corresponding to major functional groups D. Z -potential vs. pH and E. Mean diameter of 
ND agglomerates vs. pH for ND-COOH (•), ND-OH (■), and ND-NH2 (▲). Reported as 
mean ± standard deviation. Arrows indicate direction of titration for each type of ND.
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The effect of pH on Z-potential was investigated for ND-COOH, ND-OH, and 
ND-NH2 (Figure 3D) to make predictions about electrostatic interactions between 
tiopronin and NDs. ND-COOH has a strongly negative Z-potential above pH 3.8 due to 
deprotonation of ND-COOH to ND-COO-. ND-OH has a moderately positive Z-potential 
in acidic and neutral pH with an isoelectric pH 7.9, above which a negative Z-potential 
was observed. The positive Z-potential in acidic pH may result from ND-OH protonation 
or the presence of hydrogen terminations (ND-H) formed during the preparation of ND- 
OH. ND-H has been previously reported to exhibit a highly positive Z-potential for 
reasons that are not entirely clear.22-23 ND-NH2 has a weakly positive Z-potential in acidic 
pH with an isoelectric pH 6.1, above which it has a weakly negative Z-potential. Although 
ND-NH2 is expected to have a more strongly positive Z-potential in acidic pH compared 
to ND-OH, contribution from remaining COOH groups in ND-NH2 (also seen in FTIR) 
results in a surface with mixed electrostatic affinity and a lower net Z-potential. The effect 
of pH on the size of ND agglomerates was also investigated. The results are shown in 
Figure 3E. For ND-COOH, pH had a significant impact on the extent of agglomeration. 
The nominal size of ND-COOH clusters was 200 nm for pH > 4. Below pH 4, significant 
aggregation of ND-COOH was observed, with particle sizes ranging from 3.4 to 5.7 p,m. 
This observation can be attributed to protonation of the carboxylate group, resulting in 
reduction of the magnitude of Z-potential as indicated in Figure 3D and, consequently, a 
significant decrease in colloidal stability. For ND-OH, average size increased with 
increasing pH, with sizes ranging from 0.8 to 5.7 p,m. This is also in agreement with the 
Z-potential titration data, which shows that the magnitude of ND-OH Z-potential drops 
with increasing pH, leading to weaker electrostatic repulsion between individual particles
w hich confers colloidal stability. For N D -N H 2 , the effect o f  pH  on size w as m uch less 
pronounced. The average diam eter o f  N D -N H 2 agglom erates ranged from  2.5 to  3.2 pm. 
This result is reasonable considering N D -N H 2 has a m ix o f  carboxylate and am ine 
surface m oieties and exhibited only small changes in net Z-potential over the tested pH  
range.
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3.2. ADSORPTION OF TIOPRONIN
A dsorption isotherm s w ere constructed by plotting the equilibrium  tiopronin 
concentration (Ceq) follow ing adsorption vs. A, the am ount o f  adsorbed drug per gram  o f 
ND , calculated by taking the difference o f  the tiopronin  initial solution concentration (Co) 
and the equilibrium  concentration after 24 hours. The experim ental adsorption isotherm s 
(Figure 4) w ere fit by nonlinear least-squares regression to  Langm uir and Freundlich 
m odels. The L angm uir m odel (Equation 1) assum es that all adsorption sites are identical 
w ith respect to  affinity for adsorbate and energy o f  adsorption.
A = Am a x
Ceq
l+ K iC eq
(1)
This m odel also assum es that all adsorbed m olecules are in contact w ith the 
adsorbent (i.e., m onolayer adsorption).25 In E quation 1, Amax represents the m axim um  
m onolayer adsorption capacity o f  the adsorbent, and K l represents the strength o f 
binding. The Freundlich m odel (Equation 2), in contrast, accom m odates m ultilayer 
adsorption and adsorbent surface heterogeneity .26 In this em pirical m odel, K f  and n  are 
relative indicators o f  adsorption capacity and favorability, respectively.
A = K FCgqn (2)
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Figure 4. A-C. Langm uir (solid red line) and Freundlich (blue dashed line) fits to 
experim ental adsorption isotherm s o f  A. N D -C O O H , B. N D -O H , and C. N D -N H 2 . D.
Overlay o f  Langm uir fits from  A-C.
For all three N D s, R values for adsorption data fits to  either m odel are all greater 
than 0.97. Amax values for N D s change in the follow ing order: N D -C O O H  < N D -O H  < 
N D -N H 2 (Table 1). The same trend is observed for Kf  values. N either the L angm uir 
b inding strength Kl nor the Freundlich adsorption favorability param eter n follow s this 
trend: both are highest for N D -C O O H , but N D -O H  has the low est Kl , w hile N D -N H 2 has 
the low est n . Overall, the L angm uir m odel fits the experim ental data m ore closely than 
the Freundlich m odel for all three N D s investigated here. This indicates that the 
interaction o f  tiopronin w ith  the N D  surface m ay be understood largely in term s o f  the 
Langm uir m odel and m onolayer adsorption. Specifically, the param eters Amax and Kl 
derived from  this m odel can be used to  com pare the properties o f  functionalized N D s as
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adsorbents for tiopronin and to predict their relative effectiveness for different 
applications. Parameters for each of the fits, as well as the resulting Pearson’s correlation 
coefficients (R) are shown in Table 1.
Table 1. Parameters and Pearson’s correlation coefficient for Langmuir and Freundlich
curve fits to adsorption data
ND
Langmuir Freundlich
Amax (mg/g) Kl (mL/mg) R n Kf R
COOH 7.54 295 0.986 3.87 17.3 0.976
OH 42.9 49.8 0.989 2.21 118 0.971
NH2 210 76.2 0.996 2.01 824 0.980
Tiopronin is a weak acid, with a -COOH pKa of 3.9. Therefore, a significant 
proportion of the dissolved tiopronin will become negatively charged in water. ND- 
COOH exhibits negative Z-potential. Thus, the low monolayer adsorption capacity of the 
ND-COOH may be explained by electrostatic repulsion between the deprotonated ND- 
COO- and the deprotonated tiopronin. The high adsorption capacity of the ND-NH2 may 
be the result of other factors. Under the mildly acidic conditions of the adsorption studies, 
ND-OH possesses a more strongly positive Z-potential than ND-NH2 (Figure 3D), yet it 
has a lower Amax. This suggests that the higher adsorption capacity of ND-NH2 cannot be 
explained solely in terms of electrostatic attraction between positively charged surface 
functional groups and tiopronin. It therefore becomes necessary to consider the effects of 
colloidal stability on available adsorption sites. Agglomerates formed more readily by 
less positively charged ND-NH2 exhibit greater variation in available adsorption sites, 
including areas where tiopronin may accumulate and be trapped, leading to greater 
apparent Amax and binding strength of ND-NH2 27 While exhibiting a stronger electrostatic
attraction to  the anionic tiopronin, the greater net positive charge, in addition to the 
capacity for extensive hydrogen bonding w ith water, is thought to stabilize the N D -O H  
particles in the suspension, resulting in less agglom eration and few er such sites o f 
hindered desorption.
Figure 5 shows a plot o f  Amax vs. Kl for N D s w ith different surface chem istries 
studied here. A lthough the underlying m echanism s have not been w ell-established for the 
vast m ajority o f  drug-N D system s, the apparent discrepancy betw een drug binding 
strength and adsorption capacity has been reported before13-14, 26 and indicates that these 
characteristics m ay be independently tailored to  m eet the needs o f  different applications. 
The ability to  design N D  drug delivery system s w herein both loading capacity and 
binding strength can be m odified to  suit the application is extrem ely attractive, as safe 
and effective delivery o f  drugs w ith different potencies and toxicities w arrant highly 
tailorable vehicles that can carry and release the drug as required. Furtherm ore, the gap 
betw een acknow ledgm ent o f  their evident utility and com m and o f  the m echanism s 
responsible, m ay provide greater im petus for further investigations o f  N D  theranostic 
platform s.
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Figure 5. A. Kl vs. Amax B. Separation factor Rl vs. Co
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Separation factor Rl is related to  Kl by equation 3, w here Co is the initial 
concentration o f  adsorbate. The value o f  Rl indicates w hether adsorption is irreversible 
(Rl = 0), favorable (0 < Rl < 1), or unfavorable (Rl > 1) at the initial concentration o f 
adsorbate.28
R, = (3)1+K LCo
Given that Kl values ranged from  76.2 and 295 m L/m g, Rl values approach 1 as 
Co approaches 0 m g/m L and 0 as Co approaches infinity. Therefore, adsorption o f 
tiopronin onto functionalized N D  is favorable at any concentration and becom es m ore 
favorable as concentration increases.29
i
3.3. RELEASE STUDY
Tiopronin is negatively charged at physiological pH  (7.4), and therefore cannot 
readily cross the phospholipid bilayer o f  m ost cell m em branes by passive diffusion. N D - 
m ediated delivery o f  tiopronin across the m em branes in a form  o f  a thin (m onom olecular) 
adsorbed layer m ay circum vent this problem , w hile potentially im proving bioavailability 
o f  the drug. In addition, since both tiopronin and functionalized N D s have pH -labile 
protons, w e exam ined the potential for pH -triggered relase o f  tiopronin  from  NDs. 
T iopronin-loaded N D -C O O H , N D -O H , and N D -N H 2 w ere dispersed at 1 m g/m L in 
buffers ranging from  pH  4.0 to  8.1. The am ount o f  tiopronin released w as m easured daily 
for the first ten days after w hich m easurem ents w ere taken every 2-3 days. N o significant 
release w as observed beyond 12 days. To understand the effect o f  pH  on tiopronin  release 
for each functionalized ND , the cum ulative release as a percentage o f  adsorbed tiopronin
was plotted vs. time (Figure 6A-C). Additionally, cumulative release after 1 day and 12 
days was compared across the different ND surface chemistries (Figure 6D-E).
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Figure 6. A-C. Plots of cumulative tiopronin release as a percentage of the initial amount 
of adsorbed tiopronin vs. time for A. ND-COOH, B. ND-OH, and C. ND-NH2 in pH 4.0 
(•), 5.8 (■), 7.3 (▲), and 8.1 (▼) buffer. Error bars are standard error of the mean 
(o/Vri). D-E. Cumulative tiopronin release after 1 day and 12 days, expressed as D. 
percentage of the initial amount of adsorbed tiopronin and E. mass of tiopronin released 
per gram of ND. The error bars are standard error of the mean. The pH of the desorption 
buffer is indicated above each corresponding bar.
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Table 2. Calculated distribution of tiopronin microspecies and Z-potential of ND
suspensions






























*Chemicalize from ChemAxon was used for calculation of estimated microspecies 
distribution, Feb, 2019, https://chemicalize.com
Table 2 shows calculated microspecies distribution of tiopronin and Z-potentials 
determined for each functionalized ND at relevant pH levels. The majority of tiopronin is 
negatively charged over the tested pH range, with > 57% deprotonated at pH 4.0 and > 
99% deprotonated at pH 5.8 -  8.1. Thus, it was expected that release will generally 
increase under higher pH conditions which reduce the number of positive charges on the 
ND surface.
Figure 6A shows that pH had a minimal effect on the total amount of tiopronin 
released from ND-COOH. The difference in means with respect to release was 
statistically significant only between pH 4.0 and 8.1, but only after 5 days. This result is 
unsurprising since ND-COOH retains a highly negative Z-potential, even at pH 4.0. For 
this reason, ND-COOH may be useful for applications which require pH-independent 
release of tiopronin. It is also worth mentioning that because of the large number of 
negative surface charges on ND-COOH, it is much easier to maintain a small particle size 
distribution; even single-digit NDs can be prepared from ND-COOH without milling 
using salt-assisted ultrasonic deaggregation (SAUD).30 The pH also had a minimal effect
on the release of the tiopronin from ND-NH2 (Figure 6C). The difference in means can 
only be considered statistically significant between pH 6 and 7, and only after 8 days.
The Z-potential plot in Figure 3D suggests that a number of COOH moieties remain on 
the surface of ND-NH2. These groups are negatively charged within the pH range used in 
this study, contributing to the net surface charge and resulting in a low magnitude Z- 
potential. Although the means suggest that more release occurs at pH 4.0 than at pH 5.8, 
the difference between the means is statistically insignificant. The same is true for the 
means of pH 7.3 and 8.1. From a practical standpoint, no appreciable difference in release 
will be achieved by varying pH in the range of 4-8 for ND-NH2 or ND-COOH. The pH 
had the greatest effect on tiopronin release from ND-OH. The effect of pH on release 
follows a predictable trend with lower pH resulting in slower release. This effect starts to 
become significant after 3-4 days.
Figure 6D shows that ND-OH released the greatest amount of tiopronin in terms 
of percent relative to the amount adsorbed (2.6 -  13.1%) while ND-COOH released 1.8 -  
4.0%, and ND-NH2 released only 0.1 -  1.0%. However, due to the large differences in 
adsorption capacity, it is also worth comparing the mass of tiopronin that can be released 
per gram of loaded ND. Figure 6E shows that ND-OH also released the greatest amount 
of drug per gram of loaded ND (0.68 -  3.3 mg/g) while ND-NH2 released more drug than 
an equal weight of ND-COOH (0.14 -  1.4 mg/g from ND-NH2 vs. 0.12 -  0.34 mg/g from 
ND-COOH), owing to the large difference in adsorption capacity. Finally, it appears that 
prolonged release of tiopronin from ND-OH is possible under neutral or alkaline pH 
conditions since the concentration of free tiopronin continues to increase substantially 
several days after the start of the desorption experiments. In contrast, acidic conditions
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retard continued release of tiopronin beyond that which is released initially. This trend is 
present in each of the functionalized NDs, and the effect can be considered statistically 
significant in ND-OH as determined by a Bonferroni post hoc test. This may be 
beneficial for delivery of tiopronin and other thiol antioxidants since their premature 
oxidation is a concern. ND-OH may slowly release tiopronin in the acidic environment of 
the stomach. Blood plasma is buffered at pH 7.4, allowing for increased drug release after 
entering the bloodstream. Additionally, weakly acidic formulations may be prepared 
which can prevent premature release and oxidation of the drug in topical formulations.
4. CONCLUSION
Adsorption and release of tiopronin is sensitive to the changes of ND surface 
chemistry. However, due to the complexity of interactions between surface functional 
groups, drug molecules, and the environment, this effect cannot be explained by simply 
examining net surface charges. Our results show that ND-OH provides the best balance 
between drug capacity and release, making it the best candidate for applications which 
benefit from prolonged release of large amounts of tiopronin. Furthermore, formulations 
of loaded ND-OH can be prepared at an acidic pH which may be able to prevent 
premature release and degradation of tiopronin. ND-COOH has a lower adsorption 
capacity but can provide moderate release independent of pH. Additionally, ND-COOH 
is easily dispersed due to electrostatic repulsion and high magnitude of Z-potential, so it 
may be best suited for applications that require low agglomeration and can benefit from 
high surface area of ND. Finally, desorption of tiopronin may not be necessary for all
applications, so although N D -N H 2 only releases a small portion o f  its payload, it has a 
very high capacity and m ay be useful in applications in w hich it is desirable to  have 
tiopronin attached on the surface o f  dispersed N D  for prolonged release or storage in the 
body w ith subsequent local release triggered by topical application o f  ultrasound, light, 
heat, and other stimuli.
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M ethodology for the preparation o f  citrate-phosphate desorption buffers is 
provided in Table S1. The pH  8.1 buffer used for desorption experim ents w as prepared 
by dissolving 1.628 g o f  K 2H PO 4 and 0.089 g o f  K H 2PO 4 in type 1 w ater and then 
diluting to  a final volum e o f  100 m L in a volum etric flask as m entioned in Section 2.1.
Sam ple calibration curves used for the determ ination o f  M PG  in desorption 
buffers, as described in Section 2.5, are shown in Figures S2-S5. M atrix  effects w ere 
significant am ong the different buffers, bu t peak areas w ere strongly correlated to  [MPG] 
in each buffer.
Table S1. Preparation o f  citrate-phosphate buffers
pH
0.1 M
C itric acid (m L)
0.2 M
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Figure S1. Calibration curve for tiopronin in pH 4.0 desorption buffer
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Figure S2. Calibration curve for tiopronin in pH 5.8 desorption buffer
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Figure S3. Calibration curve for tiopronin in pH 7.3 desorption buffer
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Figure S4. Calibration curve for tiopronin in pH 8.1
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Our long term goal is to develop an eye drop formulation that can delay the onset 
of cataracts. Antioxidant compounds have the potential to mitigate the oxidative damage 
associated with cataractogenesis, but achieving sufficient concentrations in the lens has 
proven difficult. In pursuit of this goal, our group is investigating the potential of ND as a 
platform for improving MPG residence in the eye and reducing levels of reactive oxygen 
species and oxidative damage associated with cataract. Each investigation presented in 
this dissertation aimed to address a specific research question.
2.1. TO WHAT EXTENT DOES MPG PROTECT CELLS AGAINST ACUTE 
OXIDATIVE INSULT?
Oxidative stress was induced in A549 cells by exposure to 0.6 mM fBHP. In 
untreated cells, 0.6 mM fBHP resulted in a significant loss of cell viability due to the 
increased generation of intracellular ROS and mitochondrial superoxide, resulting in 
GSH depletion. Cells that were simultaneously treated with 0.6 mM fBHP and 5 mM 
MPG were comparable to healthy cells; however, lower doses of MPG were much less 
effective at preventing cell death. Preservation of cell viability by MPG is most likely the 
result of direct ROS scavenging, and it is clear that relatively high doses need to be 
maintained in order for MPG to be effective in this model. However, when interpreting 
these results, it is important to consider the limitations of the model used. The cells used 
in this study were from a human lung carcinoma cell line, which is not intended or
expected to fully recapitulate human lenses. Furthermore, the intense, short-lived 
oxidative insult resulting from incubating the cells in fBHP is not representative of the 
gradual damage accumulated over a lifetime of exposure to relatively low concentrations 
of oxidants. More complex models studied over a much longer time would be needed in 
order to draw any conclusions with respect to anticataract efficacy. These experiments 
are reserved for later stages of drug development. Instead, the experiments discussed here 
served as a pilot study for establishing a benchmark for MPG's antioxidant activity in a 
simplified epithelial cell model. These results can serve as a basis for comparison against 
formulations composed of MPG adsorbed onto ND, but investigations with more 
complex models are certainly warranted. Future investigations exploring the antioxidant 
activity of MPG vs. ND:MPG will utilize human lens epithelial cells, corneal epithelial 
cells, and animal models.
2.2. HOW WILL MPG BE MEASURED IN CELL AND ANIMAL MODELS?
An HPLC method was developed for the determination of MPG and MPA in 
ocular tissues and other matrices. Pre-column derivatization and fluorescence detection 
allowed for high sensitivity, and the use of a 4.6-pm core-shell stationary phase resulted 
in rapid separation. Method validation experiments demonstrated that this method would 
be suitable for monitoring MPG uptake and residence in the lens and cornea. Other 
methods were available for MPG, but they were not suitable for our application either 
due to sensitivity limitations or matrix interferences. This method is a necessary tool for 
determining the efficacy of various drug delivery vehicles, as well as the fate of MPG 
after administration to the eye. This method offers simultaneous determination of MPA,
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the primary metabolite of MPG. One of the primary reasons MPG was selected for 
investigating ND-mediated delivery is that it is metabolized to MPA, making its fate easy 
to track. Other thiol drug candidates may be more effective as antioxidants, such as the 
GSH prodrug N-acetylcysteine amide (NACA) because they can increase the size of the 
total GSH pool in addition to directly scavenging ROS. However, NACA is de-acetylated 
in vivo to N-acetylcysteine (NAC), which is then further metabolized to cysteine, which 
is used not only for GSH synthesis but also for a number of other biological reactions. 
Tracking all of these metabolites without radiolabeling would be very difficult and 
resource-intensive. In contrast, MPG and MPA are not found in untreated human or 
animal lenses, making efforts to track MPG far more reliable.
2.3. WHAT IS THE OPTIMAL ND SURFACE CHEMISTRY FOR ADSORPTION 
AND RELEASE OF MPG?
Nanodiamond powder was functionalized to produce ND-COOH, ND-OH, and 
ND-NH2, and the effect of surface chemistry on adsorption and desorption of MPG was 
determined. It would seem from these experiments that ND-OH is the most promising 
candidate for ND-mediated delivery of tiopronin. The ND-OH provided the best balance 
between adsorption capacity and sustained release. Furthermore, its release was shown to 
be the most strongly influenced by pH. Relatively low amounts of MPG were released 
from ND-OH in slightly acidic conditions, even after 12 days, but ND-OH released large 
amounts of MPG at physiological pH (7.4) and under slightly basic conditions. Since the 
cornea can tolerate eye drop formulations as acidic as pH 4, acidic preparations of ND- 
OH:MPG can prevent premature release and degradation of MPG. Upon administration 
to the eye, the pH will equilibrate with that of the ocular surface and tear film, triggering
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prolonged release o f  greater am ounts o f  M PG. Finally, N D -O H  exhibits a positive Z- 
potential at physiological pH, w hich m ay help prolong retention o f  N D -O H :M PG  on the 
cornea due to  electrostatic attraction to  the negatively charged corneal surface.
A lthough N D -O H  seem s like a clear choice for N D -m ediated delivery o f  M PG, 
there are other factors to  consider w hen optim izing N D  surface chem istry for this 
application. For exam ple, it is unclear at this tim e w hether or not M PG  needs to  be 
desorbed from  the N D  in order to  act as a scavenger o f  ROS. I f  adsorption to  N D  does 
not im pede antioxidant activity, then N D -N H 2 m ay perform  even better than N D -O H  
since N D -N H 2 can carry significantly greater am ounts o f  M PG.
2.4. FUTURE DIRECTIONS
The contents o f  this dissertation represent the prelim inary w ork necessary for the 
developm ent and evaluation o f  N D  for delivery o f  M PG  to  the eye. The tools developed 
here will play an integral role in the assessm ent o f  N D  efficacy. M oving forw ard, several 
factors need to  be considered for the successful application o f  N D :M PG  in eye drop 
form ulations aim ed at delaying cataract. Firstly, it is im portant to  investigate the effect o f 
N D  on the antioxidant activity o f  M PG  to ensure that the N D  does not hinder its ability to 
scavenge RO S and to  determ ine w hether N D  can preserve or even prom ote the action o f 
M PG. A nother key step forw ard is to  determ ine the effect o f  N D  on corneal penetration 
and lenticular uptake o f  M PG  w ith appropriate cell and anim al models.
A fter optim ization o f  the N D :M PG  eye drop form ulation, it should be tested in an 
anim al m odel o f  age-related nuclear cataract. As o f  now, there is no anim al or cell m odel 
that fully recapitulates every relevant feature o f  hum an cataractogenesis; however, the
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Emory mouse model is recommended. Cataract development in these animals mimics 
important features of human age-related nuclear cataract. In contrast with models that 
employ short-lived, high-intensity oxidative insults to induce cataracts, Emory mice 
develop cataracts spontaneously over the course of 5-6 months. This gradual progression 
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